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Preface by the CED Research and Policy Committee
CED’s Digital Connections Council (DCC), a group of information technology experts from CED trustee-
aﬃ  liated companies, was established to advise CED on the policy issues associated with cutting-edge technologies. 
Th is report, concerning “openness” in healthcare, is the third of its products. CED appreciates greatly the eﬀ orts 
of the members of the Council, and in particular, the work of DCC Chair Paul Horn, Senior Vice President, 
Research (retired), IBM Corporation, and Distinguished Scientist in Residence, Stern School of Business, Cou-
rant Institute of Mathematical Sciences and the Graduate School of Arts and Science, New York University, for 
his leadership in bringing this report to completion.  Special thanks are also due to Elliot Maxwell, CED’s project 
director and consultant, to Charles Johnson and Daphne McCurdy, CED Research Associates, for assistance 
with research, editing, and publication, and to Elliot Schwartz, CED’s Vice President and Director of Economic 
Studies.
Th is report is the work of the Digital Connections Council.  We welcome this report and recommend it to readers 
as an excellent analysis of how the system of healthcare in the United States, and importantly health outcomes, 
can beneﬁ t from the application of greater openness through digital technologies.  Th e recommendations of this 
report, along with those of CED’s policy statement, Quality, Aﬀ ordable Health Care for All: Moving Beyond the 
Employer-Based Health-Insurance System, can transform healthcare in the United States by making it signiﬁ cantly 
more eﬃ  cient, accessible, and responsive.
Patrick W. Gross, Co-Chair
Research and Policy Committee
Chairman, Th e Lovell Group
William W. Lewis, Co-Chair
Research and Policy Committee
Director Emeritus, McKinsey Global Institute
McKinsey & Company, Inc. 
Committee for Economic Development
Digital Connections Council 
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x
1Th e Digital Connections Council (DCC) of the 
Committee for Economic Development (CED) has 
been developing the concept of openness in a series of 
reports.1   We have analyzed information and processes 
and attempted to determine their openness based on 
their qualities of “accessibility” and “responsiveness.”  
If, for example, information is not available or available 
only under restrictive conditions it is less accessible and 
therefore less “open.”  If information can be modi-
ﬁ ed, repurposed, and redistributed freely it is more 
responsive, and therefore more “open.”  Based on their 
accessibility and responsiveness, information can be 
placed on a continuum of openness, stretching from 
fully open to fully closed.* 
Th e Council has found that an increased degree of 
openness often leads to greater innovation because it 
allows contributions to a work from more individuals 
whose diﬀ ering insights and experiences can add 
considerable value.  But greater openness is not always 
appropriate or desirable.  In some cases, such as an 
individual’s personally identiﬁ able information, the 
last thing one would want would be to enable someone 
to modify the information without the appropriate 
authorization. 
In other cases greater openness creates new problems.  
We can, for example, be overwhelmed by the amount 
of information available on the Internet if we lack the 
proper tools to evaluate it.  It is therefore important 
to determine, in a particular case, the degree of open-
ness likely to bring the greatest beneﬁ t, and the most 
appropriate way to deal with the problems that greater 
openness may bring.
Our goal in this report is to bring the DCC’s expertise 
in information and communications technology 
and electronic commerce to bear on those aspects of 
healthcare that have been or can be changed by the 
Internet, the continued growth in computing power 
and data storage capacity, and the increasing digitiza-
tion of information.  Th ese technological changes, 
and the greater openness that they enable, are visible 
in areas that range from biomedical research and the 
disclosure of research ﬁ ndings, through the process 
of evaluating drugs and devices, to the emergence of 
electronic health records, and the development and 
implementation of treatment regimes by caregivers and 
patients.  Bringing greater openness to diﬀ erent parts 
of the healthcare production chain can lead to substan-
tial beneﬁ ts by stimulating innovation, lowering costs, 
reducing errors, and closing the gap between discovery 
and treatment delivery.  
We have not exhaustively cataloged the healthcare 
arenas that could beneﬁ t from greater openness.  We 
have simply tried to show potential beneﬁ ts which can 
be achieved with or without a fundamental restructur-
ing of healthcare in the United States or the achieve-
ment of universality of healthcare insurance.  We hope 
others can build upon this work.
Biomedical Research
Th e report focuses ﬁ rst on the area of biomedical re-
search.  Th is realm is being transformed by the success 
of the Human Genome Project (HGP).  By mapping 
the human genome, the HGP demonstrated the 
possibilities of mass collaboration and the beneﬁ cial 
results of allowing data to be accessed immediately and 
manipulated by researchers around the world.2  Th e 
progeny of the HGP have adopted this open model 
and are ﬂ ourishing by sharing data, applications, and 
even network resources.  Th e Council recommends 
that the federal research agencies push further 
by enunciating clear policies favoring openness, 
Executive Summary
* Th e accessibility aspect of openness is closely related to “transparency” but openness as we are using it has the additional aspect of responsiveness—
permitting people other than the creator to contribute, modify, reuse, repurpose, and redistribute the work.
2funding further work on standards for protocols, 
formats, terminology and nomenclature that allow 
the sharing and manipulation of data, and support-
ing experiments with diﬀ ering levels of openness 
to determine the optimal level for research under 
various scenarios.
Clinical Trials
Questions about the openness of clinical trials have 
been raised vigorously over the last decade.  Although 
the Food and Drug Administration (FDA) had long 
required the registration of clinical trials involving 
life-threatening interventions, there have been disputes 
as to the completeness of these registrations—and 
about the lack of registration of other clinical trials.  
Advocates of greater openness here and around the 
world have been concerned not only about registra-
tions, but also about access to trial results and, perhaps 
more important, to the data that underlie the results—
and whether the data will be available in a computable 
form.   
Because clinical-trial populations do not reﬂ ect the 
broader populations that will later use the interven-
tion—or the length of time that they will use it—many 
adverse eﬀ ects are unlikely to be discovered through 
clinical trials, raising questions about drug safety and 
the processes for monitoring drug impacts after ap-
proval.  Amendments to the FDA’s enabling legislation 
in 2007 addressed these issues in part, but there are 
additional ways in which greater openness can improve 
clinical trials and post-approval surveillance.  Most im-
portant for improved healthcare research is to make 
the trial results and the data underlying trials more 
accessible more quickly in a form that is search-
able and computable using common standards.  In 
addition, applicants for FDA approval should be 
required to submit all studies they have conducted 
on the intervention with any safety-related results 
being made publicly available. 
Th e system would also be improved by further 
strengthening the protections for trial participants, 
ending split federal oversight of trials, and clarifying 
the laws regarding tissue donations.  Th e Council 
joins a long list of groups recommending far more 
comparative testing of drugs to supplement clinical 
trials that simply compare an intervention’s eﬀ ects 
with those of a placebo.
Disclosure of Results and Underlying Data
Common to both basic research and clinical trials 
are issues surrounding what results and what data 
are made public and when?   A new concern is how 
data will be published or disclosed, given the rise of 
new disclosure models, ranging from the ﬁ ling of 
human genome sequences in the open GenBank to 
new open-access scientiﬁ c and technical journals and 
open-access archives. Th ese outlets pose a serious chal-
lenge to the traditional model of publishing research in 
subscription-funded, paper-based scientiﬁ c and techni-
cal journals owned by commercial or not-for-proﬁ t 
publishers.  
Th e Council recommends federal support for earlier 
and expanded accessibility to results and data, and, 
more speciﬁ cally, the passage of legislation that 
would mandate public access to results of most 
unclassiﬁ ed government-funded research no later 
than six months after publication.  Major govern-
ment funders of research should also be receptive to 
requests for funding for the publication of research 
results in open-access journals.
Electronic Health Records
Th e emergence of electronic health records (EHRs) 
raises new openness issues.  Utilizing such records, 
caregivers at any location would have access to a pa-
tient’s medical history.  Results of tests and treatments 
could be added easily as they become available, thereby 
improving treatment, preventing duplicative testing, 
and reducing medical errors.  Eventually, EHRs could 
be constructed including family medical histories, 
genomic and pharmacogenomic data, environmental 
exposures, lifestyle and other information, easing the 
way toward the “personalization” of treatment.  Th e 
aggregation of such records, and others, could then 
facilitate the achievement of a genuine “evidence-based” 
medical system.  Such records provide far richer data 
than clinical trials, and could serve as the basis for pre-
dictive models similar to those used in other scientiﬁ c 
domains.  Th e Council recommends that federal 
eﬀ orts to develop standards for an interoperable, 
national EHR system should be given high priority.
3Privacy and Security
But the openness of the EHR that allows more ef-
ﬁ cient collection of more data and permits improved 
caregiver access raises fundamental issues of privacy 
and security that will tend to limit openness.  Who 
will have access to these records and under what 
circumstances?  How will the information be used? 
Who will make these decisions?  Whether patients 
agree to participate in an EHR system may well 
depend on whether these questions are answered to 
their satisfaction. 
Th e Council returned to the theme of the importance 
of greater federal support for the infrastructural 
aspects of openness—in this case the development 
and implementation of standards that would facilitate 
the creation and exchange of data—as well as incen-
tives for the adoption of EHRs.  To protect privacy, 
new rules will need to be extended to any entity that 
handles patient-identiﬁ able healthcare information, 
and new resources will be needed to support vigorous 
enforcement of privacy and security rules.  In order to 
foster comparative testing of drugs and treatments, 
strengthen drug and device safety monitoring, and 
spur development of evidence-based medicine and 
the generation of clinical-practice guidelines that 
would bridge the gap between discovery and treat-
ment, the Council calls for a public-private partner-
ship to create large databases made up of EHRs, 
health-insurance-claims data, and clinical-trial data, 
etc., appropriately de-identiﬁ ed to protect patient 
privacy. 
New Sources of Information for Patients and 
Caregivers
Th e Council also looked at aspects of openness related 
to new sources of information for patients and caregiv-
ers.  Patients are now able to search through a vast 
store of health-related information on the Internet 
(some good, some bad, much irrelevant) and even 
provide their caregivers with current research. Th ey 
can customize their own treatment through shared de-
cision making with their caregivers, and continuously 
contribute data through the use of remote-monitoring 
equipment.  With greater access to information about 
the quality and costs of procedures and practitioners, 
patients can become more responsible healthcare 
consumers; good caregivers should beneﬁ t as poorer 
performers are weeded out.  But information can be 
used in harmful ways such as the adverse selection of 
sicker patients or of talented, but less cost-conscious, 
caregivers.  Both patients and caregivers can beneﬁ t 
from having vastly expanded access to data, but may 
also be overwhelmed without appropriate support 
tools.  
Th e Council recommends that the federal govern-
ment move aggressively to disclose data on the cost 
and quality of healthcare providers and procedures, 
and to monitor and provide ﬁ nancial incentives for 
compliance with evidence-based, clinical-practice 
guidelines.  Given the explosion of caregiver-
aﬃ  liated enterprises that provide patient testing or 
treatment, conﬂ icts of interest by caregivers need 
to be disclosed.  In order to avoid disincentives for 
the use of remote monitoring and telemedicine, the 
federal government should review its reimburse-
ment policies and work with the states to address 
conﬂ icting state licensing and malpractice rules. 
Public Health
Th e global public health system depends on data shar-
ing and worldwide collaboration; without it, as seen 
in the Severe Acute Respiratory Syndrome (SARS) 
experience, the lives of millions are threatened.  
With lower-income countries showing reluctance 
to share data and physical evidence, the Council 
recommends greater attention to ensuring that all 
countries beneﬁ t from discoveries that result from 
the global sharing of data related to the emergence 
of new diseases.  Better electronic linkages among 
public health agencies, both globally and locally, and a 
willingness to develop new detection methods, are also 
necessary when diseases can spread at the speed of a jet 
plane.
Medical Devices
Greater openness in software-controlled medical 
devices creates new opportunities and challenges. Th e 
history of practitioner innovation in scientiﬁ c instru-
ments and the inﬁ nite malleability of software suggest 
the potential for a dramatic increase in practitioner-
driven customization of such devices.  At the same 
time, the FDA continues to have responsibility for 
assuring the safety and eﬃ  cacy of these devices and has 
4justiﬁ able concerns about post-approval changes made 
to them. Th e Council recommends that the FDA 
begin an examination of how to beneﬁ t from the 
user-driven innovation while maintaining appropri-
ate oversight for safety and eﬃ  cacy.
Conclusion
One point should be made explicit.  Some readers 
might approach this report thinking it is about health-
care and information technology—and there have been 
a number of excellent reports on that subject.3  But 
openness, while facilitated by information technology, 
should not be equated with it.  Th e beneﬁ ts of greater 
openness can be found when a caregiver is more 
attentive to a patient’s story and does not stop listen-
ing prematurely in order to narrow down potential 
diagnoses.  Greater openness is what allows us to 
improve the evaluation of interventions in clinical trials 
through patient-outcomes reporting.  When game 
hunters in Cameroon provide samples to public health 
researchers on the lookout for disease outbreaks we are 
witnessing greater openness.  Openness is ultimately 
about an attitude that sees the opportunity for many 
to beneﬁ t from greater access to information, as well as 
to contribute much to the beneﬁ t of us all.
Greater openness is likely to become increasingly 
important in more and more areas driven by the 
relentless progress of information and communications 
technology.  We oﬀ er these recommendations with 
the hope that modest changes based on greater access 
to information by more people, and more possibilities 
for them to contribute based on their own expertise 
and energy, can help improve healthcare in the United 
States and around the world.
5Th e progress of scientiﬁ c and technological knowledge is 
a cumulative process, one that depends in the long-run 
on the rapid and widespread disclosure of new ﬁ ndings, 
so that they may be rapidly discarded if unreliable, or 
conﬁ rmed and brought into fruitful conjunction with other 
bodies of reliable knowledge.” 
 - Paul David4 
For the last several years the Digital Connections 
Council (DCC) of the Committee for Economic De-
velopment (CED) has been documenting the growing 
impact of the Internet on innovation.  Its ﬁ rst report, 
Th e Digital Economy: Promoting Competition, Innova-
tion, and Opportunity (2001), provided an early gauge 
of how strongly the Internet was aﬀ ecting the economy 
a few years after the development of the World Wide 
Web and the release of the ﬁ rst commercial browser.
Th e Council’s second report,  Promoting Innovation 
and Economic Growth: Th e Special Problem of Digital 
Intellectual Property (2004), addressed an important 
consequence of the increasing digitization of informa-
tion and the global spread of Internet connectivity: the 
tension between the virtually free copying and distri-
bution of information products enabled by digitization 
and the Internet and the growing concern among 
intellectual property rights holders over the misappro-
priation of their works.  Because of this tension—and 
proposed legislation and regulatory responses to it—
the Council began to look more deeply at the process 
of innovation in the increasingly digital environment of 
the early 21st century.
Innovation, the Council noted, involves both ﬁ rst 
creators and follow-on innovators, with the latter vastly 
outnumbering the former.  But ﬁ rst creators are almost 
always follow-on innovators to some previous ﬁ rst 
creators—they too, as Sir Isaac Newton wrote, “stand 
on the shoulders of giants.”*   
Th e cycle of innovation is thus continuously sustained. 
An equitable and eﬀ ective intellectual property system 
must take into account both ﬁ rst creators and those 
who come later to build upon their work. 
Th e U.S. intellectual property system allocates rights 
between a ﬁ rst creator and those who would utilize 
that creation for another work.  Economists have 
pointed out that if the rights of the ﬁ rst creator are 
extended too far there may be too little room left 
for follow-on innovation which falls outside the ﬁ rst 
creator’s control.  Th is would result in the “underpro-
duction” of follow-on innovation.  If the rights of ﬁ rst 
creators are reduced too much, there may be too little 
ﬁ nancial incentive to spur additional creative activity, 
resulting in the underproduction of ﬁ rst creations.
Th e Council noted that for over 200 years the United 
States has been able to maintain a reasonable balance 
between the rights accorded ﬁ rst creators and follow-
on innovators.  Th e ﬁ rst creator has more rights in the 
early years after he or she creates the work.  Eventually 
the scales are tipped toward follow-on innovators when 
the work enters the public domain, freely available to 
all.  Th e Council found that the Internet, even with the 
capabilities it provides for misappropriation of works, 
has not so changed the environment as to justify a 
dramatic expansion of the rights of ﬁ rst creators (with 
a concomitant lessening of the rights of follow-on 
innovators).   After reviewing the technology and the 
law, the Council concluded that the existing balanced 
allocation of rights had proven itself suﬃ  ciently ﬂ exible 
to accommodate the emergence of new technologies 
such as the player piano, phonograph, radio and 
television broadcasting, and tape and CD recording, 
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of giants, and so able to see more and see farther than the ancients.”
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of the Internet.  Th e Council therefore rejected a call 
for vastly greater protections for rights holders and 
opposed technological mandates that would seek to 
enforce those rights in every manner of digital device.
In its next report, Open Standards, Open Source, and 
Open Innovation:  Harnessing the Power of Open-
ness (2006), the Council documented the growing 
importance of open standards in the information and 
communications technology arenas and their value in 
increasing competition and stimulating innovation.  
Th rough an analysis of the operations of the open-
source software development community, the Council 
showed the many diﬀ erent motivations that lead 
individuals to voluntarily contribute their time and 
eﬀ ort and to share their creative acts.  
Th e Council also recognized the emergence of a theory 
about how sharing one’s creation freely with others 
provides a means of adding value to it.  Traditional 
theories of intellectual property identify the principal 
incentive for creative activity as coming from the eco-
nomic returns that might be obtained by the creator.  
To obtain these returns, the rights holder must be able 
to control the creation so as to be able to charge for 
access and obtain compensation for the creative eﬀ ort.  
Th e system of intellectual property rights and licenses 
provides the means for such controls. 
Th e open-software movement also utilizes intellectual 
property rights and licenses.  Th e underlying premise 
of open software, however, is the mirror image of the 
traditional view that value is based on allowing control 
by the rights holder and facilitating the exclusion of 
others.  Open-source licensing is designed instead 
to facilitate creative acts by others based on the as-
sumption that the value of the original work can be 
increased most by encouraging the greatest number of 
follow-on innovators to contribute to it.   Open-source 
intellectual property licenses prohibit anyone from 
restricting access to, or preventing the modiﬁ cation of, 
the original work. 
Th is theory of value based on sharing focuses on 
follow-on innovators.  It is closely connected to the 
rise of the Internet, which allows more eﬃ  cient access 
to the ﬁ rst creation and more eﬃ  cient contribution of 
suggested modiﬁ cations.  Th is ability to have access 
and to make changes (responsiveness) is how we deﬁ ne 
what we call “openness.”
Th e Council concluded that both theories of value—
one based on exercising control and restricting 
access, the other based on encouraging access and 
modiﬁ cation—have places in the system of innovation.  
It noted that follow-on innovators had historically 
played an important role in innovation—such as in 
developing many of the popular modiﬁ cations of the 
ﬁ rst automobiles—and that the open-source software 
movement, with its emphasis on follow-on innovation, 
was consistent with a long history of innovation in 
America and around the world.  What the Internet has 
changed is the ability to provide access and responsive-
ness, and therefore to stimulate global collaboration on 
a mass scale.  Th is capacity to allow millions of people 
to work together and to contribute their own expertise 
has been observed by others who have labeled it an 
“architecture for participation,” the “read-write Web,” 
or “Web 2.0.” 
For this report, the DCC decided to look at how 
“openness” was being or might usefully be employed in 
the healthcare arena.  Th is area, which now constitutes 
approximately 16-17 percent of GDP, has long frus-
trated policymakers, practitioners, and patients.  It was 
the Council’s desire to bring its expertise in informa-
tion and communications technology to bear on issues 
in healthcare using the “lens” of openness to comple-
ment other work on healthcare being done under the 
auspices of the CED.*  Th us, the aim of this report is 
to identify areas where greater openness is likely to 
increase innovation, minimize costs, improve treat-
ments, reduce errors, and shorten the interval between 
research and discovery and the development of clinical 
practices based on research results.  Th e following 
report is the result of the Council’s deliberations.
* Committee for Economic Development, Th e Employer-Based Health-Insurance System is Failing: What We Must Do About It (Washington D.C.: 
CED, 2007).
7Th e patient is in crisis.
Th e symptoms are clear. 
But there is no widespread agreement on how to 
proceed.
Th at is healthcare in the United States in 2007 when:
• We spend far more than any other industrialized 
nation—according to the OECD more than twice 
as much as the median of its members—while 
having the lowest longevity rate; 5 
• Little more than one-half of patients receive care 
based on best medical practices;6 
• Less than one-half of physicians practice using 
recommended processes for care;7 
• Only one-quarter of medical practices are based on 
adequate evidence of their eﬃ  cacy;8
• $3.5 billion a year is wasted on medication errors, 
while 1.5 million patients are hurt by them;9
• Most drugs prescribed in the United States 
today are eﬀ ective in only 60 percent of treated 
patients;10
• 30 percent to 40 percent of every healthcare 
dollar—some two trillion of them or roughly 
16-17 percent of GDP—is spent on costs associ-
ated with “overuse, underuse, misuse, duplication, 
system failure, unnecessary repetition, poor 
communications and ineﬃ  ciency;”11
• We spend six times as much for administration as 
any other nation.12 
Healthcare in the United States in the 21st century is 
pre-industrial in organization. It is a combination of 
leading-edge science, practitioners organized in guilds 
similar to those of the Middle Ages, operating within 
jurisdictional boundaries determined in the 18th and 
19th centuries with a 20th century payment system.  
Th ere have been many reports on what is wrong with 
healthcare in the United States.  What follows are not 
suggestions for radical change.  Th ey are examples of 
speciﬁ c and limited reforms that, in their cumulative 
impact, could be transformative.  Th ey are changes 
that are occurring, or could occur reasonably easily, 
utilizing the power of the Internet and an approach 
that looks at all procedures and processes for improve-
ments based on two considerations: 1) will this be 
improved by providing greater access to information; 
and 2) will this be improved by allowing a broader 
group to be able to add their contributions through 
the modiﬁ cation, repurposing, and redistribution of 
information?  In other words, are there ways in which 
we can make parts of healthcare more “open” and allow 
the power of openness to aﬀ ect it as it is aﬀ ecting—
and beneﬁ ting—almost every other aspect of our 
world?
Th ere are several reasons why we have not seen more 
openness in healthcare.  As many have remarked, 
we have no healthcare “system.”  Th e marketplace is 
extraordinarily fragmented among individual and in-
stitutional players.  Th e player that pays almost half of 
the costs, the federal government, does not fully exploit 
the data it possesses and rarely exercises its power as a 
payer to improve the quality of healthcare.  Increased 
access to information is viewed as threatening by those 
who now control the information, criticized by others 
for allowing adverse selection to maximize proﬁ ts, 
and condemned as potentially compromising patient 
privacy and security.  Some licensed professionals may 
resist greater participation by others they consider less 
qualiﬁ ed.  Th e tensions between the need for intel-
lectual property protection and controlled access to 
stimulate innovation and the potential gains from the 
widespread availability of information are becoming 
increasingly clear when the consequences may be life or 
death.  
We may have assumed in the past that information 
should be held tightly unless there was a good reason 
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might instead assume that information can be shared 
and improved unless there is a good reason for restrict-
ing access or controlling modiﬁ cations.  What follows 
is an exploration of how such greater openness might 
beneﬁ t healthcare in the United States and the world 
in 2007 and beyond.
9Just weeks before the 50th anniversary of Watson 
and Crick’s article describing DNA’s double-helix 
structure, scientists produced a ﬁ nished sequence of 
the human genome, launching “the genome era.”13  
Th e mapping of over 3-billion base-pairs was an 
extraordinary accomplishment that at the same time 
demonstrated the power of an open and collaborative 
model of discovery that has become a paradigm for 
modern database-oriented biomedical research.  
The Human Genome Project’s Open Model
Like the race to discover DNA’s structure, the search 
for the human genome sequence was very competi-
tive.  Celera, a private-sector ﬁ rm led by Craig Ventor, 
sought to be ﬁ rst to establish the sequence while, 
as was the norm, keeping much of its data private, 
to be made available on commercial terms to other 
researchers.  In contrast, the publicly funded Human 
Genome Project (HGP) followed an open model 
making its data publicly available and welcoming input 
from around the world.  HGP pushed participating 
researchers to disclose their ﬁ ndings as quickly as pos-
sible.14  While Celera made important contributions to 
the sequencing, it was the HGP’s model of discovery 
that has transformed the research process by reducing 
“transaction costs and secrecy that may impede follow-
on research.”15 
Th e HGP researchers not only put raw sequencing 
data into the public domain, but as the “data were 
being produced, an open-source software program 
known as the distributed annotation system (DAS) 
was set up to facilitate collaborative improvement 
and annotation of the genome.”16  Th is allowed any 
researcher to choose the annotation they wanted to 
view and enabled the ranking of annotations by the 
number of researchers that used them, something akin 
to Google’s methods for ranking search results.17 
Th is open model is now being used in a feder-
ally funded international eﬀ ort to create a map of 
haplotypes (HapMap), which describe variations in the 
human genome that tend to occur together in “neigh-
borhoods” or haplotypes.18  Data about the genotype of 
the individual haplotypes is being released publicly as 
soon as it is identiﬁ ed.   Th e openness of the HapMap 
eﬀ ort is reinforced by its use of a licensing system that 
is “self-consciously modeled on the ‘copy-left’ system 
of open-source software licensing” and which prevents 
those who utilize the date from attempting to close it 
to others via patents.19 
Utilizing the results of the HapMap process, a public-
private partnership, the SNP Consortium, is identify-
ing panels of a few hundred thousand single-nucleotide 
polymorphisms (SNPs) that can be used to identify 
common variants in an individual’s entire 3-billion 
base-pair genome that might be associated with a 
disease.20  As with the HapMap project, participants 
in the consortium have agreed to put the data they 
produce in to the public domain.21
In the reasonably near future, according to Dr. Francis 
Collins, leader of the National Human Genome 
Research Institute (NHGRI) in the National In-
stitutes of Health (NIH), the HapMap should help 
make practical case-controlled studies using SNP’s 
to identify gene variants that “contribute to diabetes, 
heart disease, Alzheimer disease, common cancers, 
mental illness, hypertension, asthma, and a host of 
other common disorders.”22  Th at future seems nearer 
than ever today with scientists ﬁ nding correlations 
between diseases such as multiple sclerosis and breast 
cancer and speciﬁ c genetic variations.23 
In the area of “chemical” genomics the National 
Institutes of Health (NIH), as part of its “Roadmap” 
process, has established a network of chemical genom-
ics centers available to all researchers, as well as a new 
database, PubChem, that makes much of the data 
generated by the centers freely accessible.  Today’s 
drugs target only about 500 of the more than 20,000 
genes in the human genome considered “druggable” 
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even though pharmaceutical researchers have created 
libraries of hundreds of thousands of potentially 
useful compounds.24  Th e open tools established by 
NIH should help researchers identify new targets for 
research. 
Among the legacies of the HGP are the development 
of pharmacogenomics, the study of the relationship 
between pharmacological substances and genomic data 
and epigenomics, the study of proteins that control 
gene activation.25  Eventually research in these areas 
will help determine which patients will beneﬁ t from 
which drugs as well as those likely to have adverse reac-
tions, enabling practitioners to give the right medicine 
at the right time in the right amount to the right 
patient.  We are already beneﬁ ting from improved 
predictions of the need for chemotherapy in certain 
breast cancers and the potential for adverse reactions 
in particular patients to warfarin, a commonly used 
medicine to prevent blood clotting.26  Such research 
has also identiﬁ ed a drug that had been written oﬀ  for 
most lung-cancer patients but which now appears to 
be potentially lifesaving for a small number of patients 
with a particular genotype.27  
Th e velocity of discovery is likely to revolutionize the 
development and use of pharmaceutical agents.  Most 
drugs prescribed today have positive impacts on fewer 
than 60 percent of those receiving them.28  If we knew 
more about who would beneﬁ t and who would be 
harmed, we could provide more eﬀ ective therapies 
with less risk, reduce the length, size and expense 
of clinical trials (all of which are tied to the risk of 
adverse events), and get more valuable treatments to 
market sooner.29  Th e value of pharmacogenomics will 
only increase as the cost of sequencing an individual’s 
genotype continues to decline, the number of cost-
eﬀ ective diagnostic tests increase, and genomic data 
become part of medical records as is now happening 
in some leading-edge healthcare providers such as the 
Mayo Clinic and the Kaiser-Permanente system.30 
Reﬂ ecting the openness of the HGP, the National 
Institute of General Medical Sciences has funded 
grants intended to make “resources available for inde-
pendently funded scientists to form research teams to 
solve a complex biological problem that is of central 
importance to biomedical science…and that would 
be beyond the means of any one research group.”31 
Th e Alliance for Cell Signaling, one of the grantees, 
is publishing its data on the Web; all the participants 
have agreed to disavow intellectual property rights in 
their research.32  
Similarly the National Cancer Institute (NCI) of the 
NIH has established caBIG, the Cancer Biomedical 
Informatics Grid—a network for cancer research made 
up of over 50 cancer-research centers and 30 other 
organizations that voluntarily share data, tools, ap-
plications, and infrastructure.33  It has also established, 
among other initiatives, the Cancer Gene Data Cura-
tion Project which has created a database of associa-
tions between genes and diseases and genes and drug 
compounds, the National Cancer Imaging Archive 
which provides an image archive to assist in the devel-
opment of tools to detect and classify lesions, and is 
planning a Clinical Research Information Exchange 
as a common electronic infrastructure linking those 
developing biomedical therapies and those overseeing 
the drug development and approval process.34  NCI 
is also addressing the underappreciated need for the 
creation of standards necessary for data exchange by 
supporting the development of a standardized clinical 
vocabulary for cancer.
Among international organizations, the World Health 
Organization has created www.TDRtargets.org, a 
publicly accessible Internet-based clearinghouse of 
genetic information on such diseases as malaria and 
African sleeping sickness.  Th e clearinghouse is provid-
ing this genetic data on often-neglected diseases to 
assist researchers in identifying genetic targets for new 
interventions.35 
Th ese more open approaches stand out in contrast to a 
tendency in biomedical research to become “increasing-
ly proprietary and secretive” because of the importance 
of such data for potential commercial applications or 
because of competition among academics for prestige 
and career progress based on journal publication.36  In 
response to this “privatization of data,” and to harness 
the power of openness to speed the development of 
medicines and vaccines for less lucrative commercial 
markets, the Bill & Melinda Gates Foundation is now 
conditioning its grants to require researchers to share 
their results promptly so that rival teams can build on 
successes, avoid pitfalls, and eliminate redundancy.37
Th ere is growing agreement on the value of increased 
openness in pre-competitive research; the broad 
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participation of for-proﬁ t and not-for-proﬁ t entities 
in the SNP consortium is an example of open pre-
competitive research at work.38  But there remains a 
considerable tension between those who seek intellec-
tual property protection for research results and those 
who advocate greater disclosure.  Th e disputes are not 
theoretical.  Many genes have already been patented.  
A number of biomarkers are tied up by restrictive 
patent-licensing agreements.39  And patents cover tools 
critical for future research.40 
Th e HGP dealt with the patent issue from the top 
down and participants agreed to forego patent protec-
tion.  Other collaborative eﬀ orts have chosen diﬀ erent 
paths including defensive patenting (with non-exclusive 
licensing to prevent other parties from appropriating 
research results and using them in patent applications) 
and defensive publishing to thwart patent claims.41 
Some Limits on Openness
Complete openness of data is neither easy to accom-
plish nor necessarily the best answer in all cases.  Much 
work still needs to be done to establish standards for 
protocols, formats, terminology and nomenclature that 
will allow data to be combined easily.  Th e integrity of 
existing data must be protected.  Th ere may be privacy 
issues that limit accessibility as well as disputes over 
ownership and control of data.  Th ere are public policy 
questions about the wisdom of allowing free-and-open 
access to, for example, databases of pathogens.42  And 
there are contentious issues to be addressed about the 
eﬀ ects of openness and sharing in diﬀ erent parts of 
the production chain on incentives to develop com-
mercially viable products.  Given all these issues it is 
not surprising that models with varying degrees of 
openness are being tested.
Not all of the NCI’s program participants, for 
example, provide all their data to any and all comers.  
Certain materials produced with NCI support are 
shared only with participating cancer researchers.  In 
other cases, where participants in NCI programs are 
reluctant to give up control over data they have col-
lected or generated, an innovative solution has been 
crafted under which the data holder agrees to respond 
to queries from qualiﬁ ed researchers utilizing the data 
they control but will not share. 
It is clear, however, that the open model of progress 
through sharing has found great resonance in the bio-
medical research world.  Even Craig Ventor of Celera, 
a vigorous proponent of the privatization of genomic 
data, has recognized this.  He literally has been sailing 
the seven seas gathering and classifying organisms.  
Rather than charging for access to the data, he is mak-
ing it available to all through the open-access Public 
Library of Science (PLoS).43  
Recommendations Regarding Openness in 
Biomedical Research 
Th e leading federal research agencies should continue 
their support for open models of research, whether 
entirely publicly funded or in public/private partner-
ships, such as the Human Genome Project, the 
HapMap Project, or the SNP Consortium, and should 
enunciate policies with a strong preference for utilizing 
the most open models, particularly in pre-competitive 
research.  
Experiments with diﬀ ering levels of openness should 
continue as appropriate, but greater openness should 
be preferred absent strong countervailing interests.
Because the absence of agreed upon standards for 
protocols, formats, terminology, and nomenclature 
undercuts the ability of researchers to share data in its 
most usable form, the leading federal research agencies 
should increase their support for the development of 
these infrastructural underpinnings of openness.
Th e leading federal research agencies should continue 
to require data-sharing agreements from recipients 
of federal support and should, to the greatest extent 
possible, encourage recipients to share results and 
underlying data generated by the research. 
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In 2003 Andrew von Eschenbach articulated the 
challenge of closing the gap between basic research and 
the development of clinical and public health interven-
tions.  We have seen the impact of greater openness in 
basic research.  How could the processes of approving 
drugs and devices and the monitoring of the eﬀ ects of 
these interventions after approval beneﬁ t from being 
made more open?
The Societal Bargain Underlying Clinical Trials
To obtain U.S. Food and Drug Administration (FDA) 
approval for a drug or device, the intervention must be 
tested on humans as part of a multistage-clinical trial 
in which the intervention is compared for safety and 
eﬃ  cacy with a placebo.  A clinical trial such as this 
is considered “the gold standard” for human testing 
and generates the evidentiary basis for applications 
for FDA approval.  Some 10,000 clinical trials are 
conducted every year.  
Approval by the FDA does not require that the 
intervention be without risk.  Both risks and beneﬁ ts 
must be considered, as the FDA’s decision can have 
profound consequences.  When approval is denied or 
delayed those who might have beneﬁ ted are harmed; 
when approval is granted, or granted before the risks 
are understood, those who can beneﬁ t from the inter-
vention are rewarded but some suﬀ er adverse eﬀ ects.  
Th e FDA attempts to ﬁ nd the right balance, but given 
the state of our knowledge, the attempt is as likely to 
resemble art as much as science.
Until 2007, FDA rules required the registration of 
clinical trials only for interventions dealing with 
serious or life-threatening illnesses.44  (Many trials that 
did not meet these criteria have been registered at the 
same location: www.clinicaltrials.gov.)  Th e registration 
requirement was not only pragmatic—other research-
ers should know whether a drug or other intervention 
has been studied—but principled. 
 Our society recognizes a moral obligation not to do 
harm to others.  Any intervention on a participant in a 
clinical trial presents some level of risk, so some oﬀ set-
ting beneﬁ t is expected.  Society will thus authorize an 
entity to conduct a clinical trial, with its inherent risks 
borne by the individual participants, in exchange for 
the potential beneﬁ ts from the drug or device as well as 
the knowledge that is gained from the trial.  Th e value 
to society as a whole is directly related to the knowl-
edge generated and its availability.
Th is societal bargain does not always work as intended. 
Over the last decade, many questions have been raised 
about the registration of trials, the transparency of 
their conduct, as well as the accuracy and accessibility 
of their results and the data they produce.  Recent 
headlines, for example, reveal examples of fraudulent 
results and raise questions as to whether results 
have been selectively reported with negative, even 
life-threatening, evidence suppressed.45  Research has 
shown a strong publication bias favoring the disclosure 
of favorable results and disfavoring the disclosure 
of negative trials or negative outcomes.46  Studies 
reveal that research results and disclosures appear to 
be aﬀ ected by the ﬁ nancial interests of researchers 
and sponsors; research supported by entities with a 
ﬁ nancial interest in the outcome reported signiﬁ cantly 
higher positive outcomes than research supported by 
neutral parties.47 
Registration of Clinical Trials
Registration of clinical trials in the United States 
has been very uneven, despite the FDA’s regulatory 
requirements; there is little evidence that the FDA has 
made any signiﬁ cant eﬀ ort to determine if its require-
ments were met.48  In some cases, requirements for 
registered trials were met only 3 percent of the time.49
In an attempt to address the incompleteness of clinical-
trial registrations, the editors of some of the world’s 
most prestigious biomedical journals jointly published 
Chapter 3: Openness Regarding Clinical Trials and 
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a statement in September 2004 that their journals 
would not publish ﬁ ndings based on clinical trials that 
were not registered.  Analysis following the editors’ 
announcement demonstrated a spike in compliance 
with registration requirements, at least arguably due to 
the importance, both scientiﬁ cally and commercially, 
of publication in these journals.50  (We discuss issues 
regarding publication/disclosure in Chapter 4.)
An extensive examination of the issues surrounding 
clinical-trial registrations, including what data should 
be disclosed and when, has taken place over the last 
several years in Geneva under the auspices of the 
World Health Organization (WHO) International 
Clinical Trial Registry Platform.51  Th e WHO began 
an eﬀ ort to establish a universal set of minimum data 
requirements for clinical trials based on the need of 
researchers to have access to the broadest possible 
array of compatible data and to increase the eﬃ  ciency 
of clinical research by preventing unnecessary duplica-
tion.52  Th e WHO also sought to provide guidance to 
lower-income countries facing an increasing number 
of clinical trials within their jurisdictions and lacking 
well-developed regulatory structures.  At the same 
time, major private-sector sponsors of clinical trials 
were attempting to harmonize clinical-trial reporting 
requirements around the world in order to reduce the 
costs of complying with diﬀ ering regimes.  
Although the aims of the WHO were broadly shared 
among the various stakeholders, and the ﬁ nal list of 
twenty data elements to be required for registration 
were largely agreed to, the various stakeholders were 
ultimately unable to reach agreement as to when trials 
would have to be registered and when certain data 
elements would have to be disclosed.  Th e principal 
argument against early disclosure was that “prema-
ture” disclosure would stiﬂ e innovation.  Premature 
disclosure, it was argued, would alert competitors who 
might use the data for their own patent applications.  It 
would hinder companies in their eﬀ orts to obtain intel-
lectual property protection and to commercialize the 
products being tested, thus reducing their incentives 
for research.53  Private-sector trial sponsors suggested 
postponing registration until the initiation of larger, 
later-stage trials (stages III and IV), and placing the 
data that is generated in escrow with an independent 
third party to be disclosed at the time of the approval 
of the drug or device.54  
Proponents of earlier disclosure noted that many trials 
never progress to these later stages; there were good 
reasons to disclose the results of early stage trials, even 
those deemed to have “failed.”55  Th ere is no convinc-
ing justiﬁ cation, they argued, to waste scarce research 
resources on work already done, and there may well be 
important data gathered on the safety (and eﬃ  cacy) 
of interventions in the earliest stages.56  Proponents 
of early and full disclosure point to the peer-reviewed 
Journal of Negative Results in Biomedicine and PLoS 
Clinical Trials, which publishes trial results irrespec-
tive of the outcomes, as proof of the scientiﬁ c value of 
learning from what does not work.57  (One can imagine 
that at least some participants in clinical trials would 
have second thoughts about their participation if they 
knew that the results might be kept secret.)
After completion of its consultation, the WHO’s In-
ternational Clinical Trials Registry Platform rejected 
the arguments for delayed disclosure, noting the wide 
variation in disclosure practices about trials among 
trial sponsors and the availability of information about 
the trials from other sources.58  It called for the “regis-
tration of all interventional trials, including early-phase 
uncontrolled trials in patients or healthy volunteers” 
and for “full public disclosure of all registration data 
items at the time of registration and before recruitment 
of the ﬁ rst participant.”59
It is beyond the scope of this paper to answer deﬁ ni-
tively the core questions as to the impact of the data-
disclosure requirements proposed by WHO’s Inter-
national Clinical Trials Registry on innovation and 
how the impact might vary based on the timing of the 
disclosures. A number of countries adopted the WHO 
requirements, although the United States initially took 
a diﬀ erent path, with the FDA arguing that it did not 
have the authority to impose such requirements.60  
Congress recently passed and the President has signed 
the Food and Drug Administration Amendments Act 
of 2007 (hereinafter referred to as the 2007 Amend-
ments) which requires the registration of all clinical tri-
als and the ﬁ ling of all results in a results database; the 
FDA is to study what disclosures should be required.61  
Given the complexity of the issue, it would be helpful if 
a neutral and expert party such as the National Acad-
emy could conduct a public study, speciﬁ cally with 
input from the FDA and NIH, on the optimal timing 
15
of disclosures of registrations and results, considering 
the potential impacts on innovation, the progress and 
eﬃ  ciency of biomedical research, and patient safety.
Th e 2007 FDA amendments did not resolve all of the 
important issues about openness in clinical trials.  We 
believe that the following steps would further improve 
the utility, safety and eﬃ  cacy of clinical trials:   
• Th e existing registry, www.clinicaltrials.gov, 
should be continued and strengthened, as it is the 
largest and most advanced clinical-trial registry in 
the world.  Any results database should build upon 
this infrastructure and existing trial records.
• Each trial should be issued a unique identiﬁ er 
so that the trial can be tracked through various 
reviews and over time.  As more and more trials 
are taking place internationally a solution that 
has each registry issuing its own unique identiﬁ er 
is unlikely to be the best long-term solution.  A 
more appropriate solution might be found in the 
WHO’s plan to issue a Universal Trial Reference 
Number for all trials worldwide; another pos-
sible solution would be to use some variant of the 
Internet’s domain name registry system.
• Companies seeking FDA approval for an interven-
tion are not required to ﬁ le all the studies that 
they have conducted regarding that intervention, 
just those conducted for purposes of obtaining 
approval.  Th e vast majority of other, non-ﬁ led, 
studies are never published.  All company studies 
of the agent should be made available to the FDA, 
decreasing any incentive to submit only the most 
favorable; any study relevant to the agent’s safety 
should be publicly available.  Similarly the FDA 
should consider providing access to any FDA 
studies it conducted during the approval process.
• Th ere is still much to be learned about how to 
measure trial outcomes.  NIH is now building 
a pilot results database with information from 
NIH-funded trials.  Th e National Library of 
Medicine is funding TrialBank, which will provide 
open access to computable trial results.62  Based on 
the experience with these databases, it should be 
possible to make more informed judgments about 
what data should be made available and when, and 
what conditions would maximize the utility of the 
data.  
Data Integrity in Clinical Trials
Th ere have recently been allegations of fraudulent data 
being incorporated into reports on clinical trials and 
of abuse of clinical data by sponsors.63  Such actions 
fundamentally undercut the value of clinical trials 
and strike at the heart of the drug and device approval 
processes.  Although present regulations appear to 
permit the reporting of fraudulent data to be delayed 
until approval is sought for the drug or device being 
trialed, legislation should make clear that evidence that 
would lead a reasonable researcher to conclude that it 
is likely that clinical trial data has been fraudulently 
altered should be reported immediately.64
To further safeguard the integrity of clinical trials, 
any agreements that limit the ability of researchers to 
freely discuss their ﬁ ndings, particularly with respect 
to potential problems, should be disclosed.  Th e 
legitimate goal of protecting proprietary information 
can not justify a “gag order.” 
Confl icts of Interest in Clinical Trials
Recent research strongly suggests that the conduct and 
reporting of clinical trials can be aﬀ ected by ﬁ nancial 
interests.65  With private sector funding playing a 
larger role in support of research, and with growing 
ties between academic researchers and commercial 
enterprises, it is important to disclose potential 
conﬂ icts so that those who rely upon these studies can 
make more informed judgments about them.  Here, as 
in other areas, “sunlight is the best disinfectant.”66 
Access to Data Produced in Clinical Trials
Even more contentious than the issues surrounding 
registration of clinical trials and reports of results is 
the issue of access to the underlying data generated by 
the clinical trials.  Such data are not generally available 
even after the trials are completed and the drugs or 
devices approved; in fact, the data can be protected by 
law for an additional period of time after the FDA has 
acted.67 
Th ese data may well still be of value to the trial’s spon-
sor.  But their value to the research community at large 
is likely to be even greater.  Moreover, even if the data 
are disclosed the sponsor does not lose all of its beneﬁ ts 
having had a multiyear head start in analyzing the data 
and preparing itself to act upon that analysis.68 
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The Need for Usable Data
Researchers now read journal articles about the results 
of trials in hard copy or in Microsoft Word or PDF 
ﬁ les and generally lack access to the underlying data.  
But, as one student of clinical trials has noted, comput-
ers don’t read journals, they process data.  Imagine the 
added value to a researcher of access to the underlying 
data from a journal article.  Th en imagine the added 
value to society of a searchable database containing the 
aggregated data underlying multiple clinical trials.
Th e present situation is in stark contrast.  Most of the 
data from applications to the FDA lies in a “bottomless 
pit,” and “is not cataloged, tagged, or in any usable 
form that would allow it to be found.”69  
In the past, the FDA has not required that applica-
tions be submitted in electronic form or speciﬁ ed 
data formats.70  Ultimately, policymakers will have 
to determine what types of data from clinical trials 
ought to be disclosed and when, but it is increasingly 
important that if data are made available they should 
be in a searchable computable form—interoperable 
at both a semantic and syntactical level—allowing for 
interpretation both statistically and medically.71  Th is 
is no easy task.  It will require signiﬁ cant eﬀ orts to 
reach agreement on the appropriate standards, but the 
potential gains are enormous. 
Informed Consent for Participation in Clinical 
Trials 
No matter how important the trial, the protection of 
the patient must be a central concern. To ensure that 
the rights of patient participants in clinical trials are 
protected, it is important that they have access to and 
understand the conditions of participation, the risks 
involved, as well as the potential beneﬁ ts, and any 
potential conﬂ icts of interest.  Th ere are no general 
rules that apply to clinical trials and, surprisingly, there 
is no single federal agency with authority over them.72  
Given recent examples that suggest that participant 
consent has been less than informed, it would be 
helpful for expert federal agencies to help craft gener-
ally applicable rules regarding consent.73  In addition, 
those who recruit participants should make clear any 
ﬁ nancial stake they have in such recruiting. 
Th e website www.clinicaltrials.gov now provides useful 
information for those seeking to identify relevant 
clinical trials in which they might participate, as well 
as providing information that can help them make de-
cisions about whether to enroll.  Th is resource should 
continue to be enhanced as the 2007 Amendments are 
implemented. 
Informed Consent for the Use of Tissue 
Samples in Clinical Trials
Almost three-quarters of trials submitted to the 
FDA are based on the use of patient-tissue samples.74  
Th e willingness of patients to provide such samples 
in the future is crucial for the success of biomedical 
research, and there are signs of a growing reluctance 
on the part of individuals to provide samples without 
compensation when the samples might be used by 
others for commercial purposes without any beneﬁ t for 
the donor.75  Here too there are no general rules, and 
the law is unclear.  Th e expert federal agencies should 
make recommendations as to the appropriate balance 
between the rights of donors and the needs of research-
ers, including what kinds of disclosures of risks and 
beneﬁ ts are required, and what would constitute 
informed consent.  
Ideally the patient should be informed of all the uses 
that will be made of the donation.  But it is obviously 
diﬃ  cult to predict all the uses—remember that scien-
tists recently used tissue samples obtained during the 
great ﬂ u epidemic of 1918 to better understand the 
potential for future pandemics.  Even so it is important 
to be open about existing plans and to consider care-
fully whether additional consent should be required in 
the future, and under what circumstances.
Given the extraordinary pace of developments in 
genomics, pharmacogenomics and related ﬁ elds, the 
FDA should consider whether DNA samples should 
be requested as a matter of course from all clinical-trial 
participants, especially as the cost of sequencing an 
individual’s genome falls.  Eventually, it seems likely 
that genomic data will be an important component of 
the data produced by any well-conducted clinical trial. 
Privacy and Clinical Trials
Participants in clinical trials have important privacy 
interests and should be conﬁ dent that information 
about them is not disclosed to unauthorized parties or 
used for purposes to which they have not consented.  
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Expanded collection of genomic data would only 
increase the privacy stakes.  Recent litigation raises the 
issue of whether privacy protections can be maintained 
when the results of clinical trials are subpoenaed.76 
Policymakers should carefully examine how to protect 
the privacy of clinical-trial participants while ensur-
ing that appropriate information is made available in 
related litigation.  If personally identiﬁ able information 
is disclosed, either to unauthorized parties or pursuant 
to legal order, trial participants should be notiﬁ ed.
Post-Approval Surveillance
While properly conducted and reported clinical trials 
are the “gold standard” for determining the eﬀ ect of 
an intervention on the trial population during the trial 
period, clinical trials have important limitations.  Th ey 
are very expensive.  Th ey take a substantial amount 
of time to complete.  More important, it is not clear 
whether they are truly generalizable or eﬀ ective in 
predicting safety and eﬃ  cacy over longer periods of 
time by larger groups of users.
Clinical-trial populations have been justiﬁ ably criti-
cized for not adequately reﬂ ecting the much larger 
populations, particularly minority and older popula-
tions and those with multiple medical conditions, who 
will ultimately use the intervention if it is approved.77  
Th e relatively limited durations of trials do not allow 
them to predict long-term adverse results or demon-
strate long-term eﬀ ects.78   It is not surprising then 
that the exposure of a drug or device to a much larger 
population with much greater individual variation 
for a much longer period of time will sometimes lead 
to unpredicted consequences; these include not only 
adverse events not foreseen at the time of approval but 
also the development of evidence of eﬃ  cacy in treating 
conditions that had not been the subject of the trial. 
Recognizing these limitations of clinical trials, the 
FDA has often required, as a condition of approval, 
post-authorization follow-up studies.  Th e agency 
has also established a system, MedWatch, to receive 
reports on post-approval adverse events.79   In response 
to reports of adverse events, the FDA has convened 
expert advisory councils to make recommendations 
about changing drug labels, imposing new conditions 
on use, or even ordering drugs oﬀ  the market.
Th ese processes have not always worked as intended.  
As many as thirty-ﬁ ve percent of the post-approval 
studies mandated by the FDA may never have been 
ﬁ led or completed as required.80  Th e Inspector Gen-
eral of the Department of Health and Human Services 
(HHS) reported that the FDA did not know the fate 
of these studies and made little eﬀ ort to follow up.81  
Th e Institute of Medicine has called for a better system 
of adverse-event reporting.82  And more major drugs 
have been withdrawn from use in recent years than at 
any time since 1990.83 
Th e 2007 Amendments greatly increase the availabil-
ity of information regarding post-approval surveillance 
monitoring.  Th ey grant new powers to the FDA 
regarding post-approval studies—such a study, for 
example, served as the basis for the 2007 re-evaluation 
of Avandia—as well as post-authorization reporting.84  
Some 449,000 adverse events were reported in 2006.  
Many experts believe this represents only a small 
percentage of actual problems.85  Th e 2007 Amend-
ments direct the FDA to contract with private-sector 
entities, such as healthcare providers or insurers, to 
use massive databases (100 million records or more) of 
patient records to identify possible safety issues related 
to drugs and devices.86  Advocates for such a use of 
massive databases believe that it will facilitate the 
earlier discovery of adverse eﬀ ects from drugs such as 
Vioxx.87  (We will discuss the use of such databases in 
evidence-based medicine in Chapter 5.)  
Additional steps may be desirable. Th e FDA should 
consider creating incentives for the reporting of adverse 
events, broadening the means by which interested 
parties can report them, and increasing access to the 
reports that are received.88  
Greater disclosure raises issues such as the potential 
for misinterpretation of reports and the gaming of 
FDA processes by competitors.  But these possibilities 
are outweighed by the gains from having the active 
participation of patients and practitioners who experi-
ence adverse reactions on medicine’s front lines.89  
Practitioners are already seeing the beneﬁ t of using the 
Internet to share such reports with each other, without 
waiting for FDA action, in order to improve their own 
practice of medicine.90
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Comparative Testing
As one expert put it, for a new drug to be approved 
by the FDA it “must merely be slightly better than 
(the) placebo in achieving a surrogate outcome over 
a few months, in modest numbers of highly selected 
patients.”91  Is this really all we need to know?
Billions of dollars are spent each year on groups of 
drugs that act in similar ways.  For caregivers and 
patients to make more informed decisions, they need 
to know whether one intervention is superior to 
another for a particular patient or group of patients.  
Such information does not normally emerge from the 
FDA’s drug approval process.  Individual companies 
are unlikely to undergo the expense of conducting 
rigorous comparative trials. If healthcare resources are 
not inﬁ nite and if better, more cost-eﬀ ective care is the 
goal, we should identify the best possible sources for 
comparative testing and fund them accordingly.  
HHS’s Agency for Healthcare Quality and Testing 
and the NIH Center for Transitional Medicine may be 
equipped to conduct such studies but they are inad-
equately funded to undertake such eﬀ orts.  In a recent 
report the CED suggested the creation of a new entity, 
the Institute for Medical Outcomes and Technology 
Assessment, which would “assess the eﬀ ectiveness, 
cost, and overall value of health interventions and prac-
tices.”92  Whatever the vehicle, rigorous comparative 
assessments are both critical and largely unavailable to 
caregivers and patients alike.   
Recommendations Regarding Clinical Trials 
and Post-Approval Surveillance
Support for the government’s leading clinical trials 
database (www.clinicaltrials.gov) should be enhanced 
so that it will include all clinical trials in the United 
States, whether publicly or privately funded, as well 
as information useful for individuals searching for 
relevant clinical trials and guidance for those seeking 
to participate in them.
Th e United States should work to promulgate a 
universal clinical-trial reference-number system so that 
clinical trials may be more readily tracked globally.
NIH should continue its work to increase the avail-
ability of the results of clinical trials, starting with 
the results of trials funded by the federal government.  
Th is work should inform any FDA decision on the 
appropriate conditions for disclosure of data generated 
by clinical trials as well as on standards to improve the 
utility of such data for biomedical research.  
To assist the FDA in setting requirements for clinical 
trials and approving drugs and devices, the National 
Academy should be commissioned to conduct a study 
and prepare recommendations as to the nature and 
timing of clinical-trial registrations and disclosures of 
data generated by clinical trials and other submissions 
to the FDA, based on the impact on innovation, the 
progress and eﬃ  ciency of biomedical research, and 
patient safety.  
Th e National Academy should be commissioned to 
conduct a study on the state of the existing law regard-
ing the rights of patients and the use of their tissues 
or ﬂ uids in biomedical research, including issues of 
consent, privacy, and payment, and make recommen-
dations as to whether changes are required.
Th e FDA should review existing requirements as to 
patient consent to participate in clinical trials and 
make changes as appropriate. Th e bifurcated authority 
in this area should be ended.
Th ose recruiting participants for clinical trials should 
be required to disclose any ﬁ nancial interest in the 
recruitment.
Th e FDA should consider whether to require DNA 
samples to be taken of participants in clinical trials 
when the price of individual sequencing declines 
to a level where mass sequencing can be done cost 
eﬀ ectively.
Th e FDA should require electronic ﬁ ling for all drug 
and device approvals.  Th e Agency should set stan-
dards for and require the ﬁ ling of data in a form that 
allows subsequent machine aggregation, search, and 
manipulation.
Th e FDA should require the ﬁ ling of all studies that an 
applicant has commissioned on a drug or device that is 
being submitted for approval, whether or not the study 
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was commissioned as part of the application.  Any 
studies reﬂ ecting safety issues should be made public. 
Th e FDA should consider making public any stud-
ies that it conducts in the course of a drug or device 
approval.
Th ose conducting clinical trials should be required to 
report to the FDA, upon detection, any instances that 
would reasonably suggest the use of fraudulent data.
Th e FDA should require disclosure of any limitations 
on researchers’ ability to comment on clinical trials 
with which they are involved.
Th e FDA should require reporting on the progress of 
all required post-approval studies.
FDA should broaden the means by which post-approv-
al adverse events can be reported and should make the 
reports more widely available.
Th e FDA should encourage the disclosure of post-
approval data indicating the eﬃ  cacy of interventions 
for non-approved purposes.
Th e federal government should dramatically increase 
its eﬀ orts to directly compare the safety and eﬃ  cacy of 
similar drugs and devices.
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Scientifi c and Technical Publishing
Scientiﬁ c and technical journals are the traditional 
vehicles for disclosure of results of basic research and 
clinical trials.  Scientiﬁ c-and-technical publishing is 
a major commercial activity with industry revenues 
upward of $7 billion annually.93  It is estimated that 
some 2.5 million research articles are published each 
year in over 24,000 peer-reviewed journals.94  Most of 
these journals are owned by commercial publishers, 
although some of the most highly regarded and widely 
distributed are published by not-for-proﬁ t “learned 
societies” such as the American Chemical Society.  
Th ere is a hierarchy of scientiﬁ c-and-technical pub-
lications.  For researchers in both the for-proﬁ t and 
not-for-proﬁ t sectors, publishing in a leading journal is 
important for advancement as well as to gain attention 
for one’s work. 
Most journals only publish articles that have survived 
a “peer-review” process with the most prestigious 
being the most selective.  Th e peer-review process has 
anonymous experts in the appropriate ﬁ eld review a 
submitted manuscript and make recommendations 
as to whether it merits publication and, if so, what 
changes would improve it. 
Th is process has a long history and many admirable 
attributes.  At its best it provides free and valuable 
assistance to journal editors, allowing them to receive 
an unvarnished critique from an expert in a ﬁ eld about 
which they may know little.  It may detect analytic or 
methodological errors, raise design issues, challenge 
assumptions, point to overlooked research, prevent 
duplication, and discourage cronyism by the editors.  
On the other hand, the process, as applied, has signiﬁ -
cant limitations that are sometimes overlooked.95  It 
does not serve as an independent check on the integrity 
of the underlying data or the processes by which data 
are collected.  It may not reveal even extensive fraud.96 
(Only access to the data and a chance to replicate 
the research itself would allow outright fraud to be 
caught.)  
A recent explosion of corrections and retractions in 
leading journals conﬁ rms these limitations.  A New 
York Times headline captures the problem:  “For 
Science Gatekeepers, A Credibility Gap.”  Th e article 
which bears this headline roots some of the problems 
in both organizational and very human terms: “eco-
nomic pressures for journals to avoid investigating 
suspected errors, the desire to avoid displeasing the 
authors and the experts who review manuscripts, and 
the fear that angry scientists will withhold the manu-
scripts that are the lifeline of the journal putting them 
out of business.”97
Limits on Openness in the Present Model
Th ere are, from the standpoint of openness, three seri-
ous problems with the traditional journal-publishing 
system.  Th e ﬁ rst is that the costs of subscriptions or 
licenses have been rising, putting them out of the reach 
of many subscribers.98  Prices for subscriptions have 
climbed four times faster than the rate of inﬂ ation in 
the recent past, increasing some 300 percent over the 
last twenty years, leading some institutions to cut back 
on their subscriptions, thus reducing access to cutting-
edge research results.99  Researchers in poorer coun-
tries are most at risk, having to rely on the generosity 
of others, including the WHO’s HINARI program, 
which provides free or almost-free access to journals for 
many poorer countries.100  If researchers do not have 
access to the results of others’ work, it is far more likely 
that they will duplicate it, and it is a certainty that they 
cannot build upon it.
Th e second problem is that the intellectual property 
rights that protect the content and underlying data 
of many of the journals prevent those researchers 
who do have access from doing what researchers 
are most skilled at—adding to, revising, modifying, 
repurposing, and reusing the content to generate new 
Chapter 4: Encouraging Openness in Publication/
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knowledge.  Some of these actions might be possible 
under today’s intellectual property rules, but research-
ers without access to underlying data may be prevented 
from making use of new and powerful computational 
techniques such as machine aggregation and manipula-
tion of data. 
Finally, as has been true in other areas where informa-
tion is being digitized, journals are increasingly provid-
ing electronic versions under license.  Th ese licenses 
may cut oﬀ  a subscriber’s access immediately and even 
limit access to older collections, include some, but not 
all, of the journals that had previously been available, 
and prevent researchers from transferring journals to 
new institutions if they change employers. Th e practice 
that some large multi-journal publishers employ of 
providing discounts to subscribers who take a “bundle” 
of publications to ensure access to one or two “must-
have” journals tends to increase the larger-publishers’ 
share of an institution’s subscription budget, threaten-
ing smaller-journal publishers and learned societies.
New Open Alternatives Emerge
But digitization and the Internet have done more than 
create the opportunity for publishers to put journal 
content in a digital lockbox.  Th ey have created new 
means for providing “open access” whether via open 
digital archives or alternatives to the traditional-
journal regime in the form of “open-access” publishing.
In 1991, Paul Ginsparg created “arXiv” as an open 
digital archive for preprints (now often called e-prints) 
in physics.101  Submissions poured in.  ArXiv has 
expanded to include mathematics, computer science, 
and, most recently, quantitative biology and now holds 
over 400,000 e-prints.102  Some academics, particularly 
those outside of physics and mathematics, have resisted 
posting their materials to arXiv and other open 
archives because of a concern that journals might not 
accept their manuscripts if the materials had already 
been deposited in an open archive; ironically, by not 
posting they substantially delayed wider access to their 
ﬁ ndings.
In 1994, Stevan Harnad broadened the debate about 
open-access science.  His “subversive proposal” rested 
on an obvious fact—researchers, particularly academic 
researchers, have a tradition of sharing, and want to get 
their results to as many of their colleagues as possible 
as quickly as possible (for many reasons, both public 
spirited and private-interest enhancing).  Harnad 
showed how electronic archiving could achieve these 
aims.  Researchers would no longer have to rely exclu-
sively on intermediaries such as journal publishers but 
could—and should, according to Harnad—create pub-
licly accessible digital archives of their own works.103
Th e potential for open-access publishing—moving 
beyond depositing preprints into archives to Web-
based publications unconstrained by subscription 
requirements or paper-based publishing formats—was 
bolstered by pioneering journals from the Optical So-
ciety of America in 1997 and the Institute of Physics in 
1998 and later by the larger-scale and more ambitious 
Public Library of Science.  Open-access publishing has 
increasingly been endorsed by academics and policy 
makers.  As the Budapest Initiative put it in 2002, “An 
old tradition and a new technology have converged to 
make possible an unprecedented public good.”104 
The Advantages of Openness
Th ere is no generally agreed-upon deﬁ nition of open-
access publishing but some elements are constant—the 
removal of cost barriers imposed by subscription and 
licensing fees, and any other conditions on access.105  
Proponents of open-access publishing claim that more 
than 2,500 open-access journals now exist, providing 
clear beneﬁ ts over traditional subscription-based paper 
publications.106  In launching the Public Library of 
Science’s open-access journal PLoS Biology, Patrick 
Brown, Michael Eisen, and Harold Varmus explained 
why they believed they were making the information 
they would publish more valuable:
Freeing the information in the scientiﬁ c 
literature from the ﬁ xed sequence of pages and 
the arbitrary boundaries drawn by journals or 
publishers—the electronic vestiges of paper 
publication—opens up myriad new pos-
sibilities for navigating, integrating, ‘mining’, 
annotating and mapping connections in the 
high-dimensional space of scientiﬁ c knowledge. 
Consider how the open availability and free-
dom to use the complete archive of published 
DNA sequences in the GenBank, EMBL, 
and DDBJ databases inspired and enabled 
scientist to transform a collection of individual 
sequences into something incomparably richer.  
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With great foresight, it was decided in the 
early 1980’s that published DNA sequences 
should be deposited in a central repository, in 
a common format, where they could be freely 
accessed and used by anyone.  Simply giving 
scientists free and unrestricted access to the 
raw sequences led them to develop the powerful 
methods, tools, and resources that have made 
the whole much greater than the sum of the 
individual sequences.  Just one of the resulting 
software tools—BLAST—performs 500 tril-
lion sequence comparisons annually!  Imagine 
how impoverished biology and medicine 
would be today if published DNA sequences 
were treated like every other kind of research 
publication—with no comprehensive database 
searches and no ability to freely download, 
reorganize, and reanalyze sequences.  Now 
imagine the possibilities if the same creative 
explosion that was fueled by open access to 
DNA sequences were to occur for the much 
larger body of published scientiﬁ c results.107
Th e Public Library of Science, an admittedly inter-
ested party, has published several papers attempting to 
compare the performance of open-access models with 
those of traditional publishing.  Th ese studies found 
that there were higher rates of citation for online open-
access materials during the early months of availability 
when only subscribers to traditional journals would 
have had access to non-open access articles.  More 
encouraging to open-access advocates were the ﬁ ndings 
that the positive gap in citation rates continued after 
six months when formerly restricted articles were made 
more broadly available.108  Th e research also suggests 
that a broader, more cross-disciplinary audience used 
the open-access materials.109  Th is is particularly 
encouraging because research has found that scientists 
working together with those in diﬀ erent ﬁ elds are more 
likely to solve scientiﬁ c problems.110 
Certain advantages are inherent in open-access 
publishing.  Open-access publishing can reach more 
people because more people have access.  More people 
can reach-open access materials more quickly than can 
reach articles available only in traditional journals.
One traditional-journal editor criticized open-access 
publishing because “substandard science could be 
widely circulated without being subjected to more 
rigorous peer review.”111  Greater openness does raise 
important issues.  But this is not one of them.  Open-
access journals, like traditional journals, are typically 
peer reviewed.  And to the extent that open-access 
journals provide access to data underlying their articles 
they provide a means superior to traditional peer 
review for replicating research and detecting fraud.  
Open access in fact can provide new methods for 
evaluating materials.  Having material available to 
anyone creates a vastly greater number of potential 
“reviewers” in the form of readers of the article.  All of 
these potential “post-publication peer reviewers” can 
track comments and changes, and comment accord-
ingly, thereby creating an annotated version that would 
not otherwise exist.112  
Openness and Government-Funded Research
A special case of open access concerns disclosure of the 
results of government-funded, non-classiﬁ ed research.  
Th e OECD Ministerial of 2004 focused on this issue; 
this led to a 2007 OECD Recommendation Concern-
ing Public Access To Research Data from Public 
Funding, which notes the beneﬁ ts of improved access 
to, and sharing of, data in terms that could be applied 
well beyond publicly funded research: 113
• Reinforces open scientiﬁ c inquiry,
• Encourages diversity of analysis and opinion,
• Promotes new research,
• Makes possible the testing of new or alternative 
hypotheses and methods of analysis,
• Supports studies on data-collection methods and 
measurement,
• Facilitates the education of new researchers,
• Enables the exploration of topics not envisioned by 
the initial investigators, and
• Permits the creation of new data sets when data 
from multiples sources are combined.114 
Th e OECD Recommendation, citing a U.S. National 
Research Council Report, states: “Th e value of data 
lies in their use.  Full and open access to scientiﬁ c 
data should be adopted as the international norm for 
the exchange of scientiﬁ c data derived from publicly 
funded research.”115  Open access should be “easy, 
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timely, user-friendly, and preferably Internet based.”116  
Such a regime, according to the Recommendation, not 
only “helps to maximize the research potential of new 
digital technologies and networks, but provides greater 
returns from the public investment in research.”117
Following the OECD’s lead, the European Com-
mission has agreed to provide millions of dollars in 
funding to support the creation and maintenance of 
an open-access digital repository.118  CERN, Europe’s 
leading high-energy physics organization, announced 
that it will only publish the results of its supercollider 
trials in open-access publications.119 
In the United States, the National Institutes of Health 
have taken the lead in pushing for broader disclosure 
of the fruits of government-funded research.  NIH 
has “recommended” that funding recipients “submit 
an electronic version of the author’s ﬁ nal manuscript 
upon acceptance for publication,” although NIH 
policy does allow the author to designate a timeframe 
for public release anytime within 12 months of ﬁ nal 
publication.120  Th is recommendation, explicitly not a 
requirement, has largely been ignored, with fewer than 
5 percent of grantees complying.121  Like NIH, the 
NSF requires that grantees provide a data-sharing plan 
but has not required “open access” to the results of its 
funded research.122 
Th e proposed Federal Research Public Access Act, 
introduced in 2006 with both liberal and conserva-
tive support, would require that unclassiﬁ ed research 
funded by any U.S. government agency that makes 
research grants totaling more than $100 million annu-
ally would have to be made public within six months 
of publication.123  Conservative supporters of the 
legislation who might have been expected to champion 
private-sector publishers argued that the research was 
paid for by taxpayers who should not have to pay twice 
by having public institutions pay for journal subscrip-
tions.  Th e House and Senate appropriations bills 
(funding NIH) include a similar provision for access 
within 12 months, but passage of the Public Access 
Act would highlight the policy of greater openness 
with respect to government-funded research.124 
Differing Models for Openness
Just as there is no agreement as to the precise 
deﬁ nition of open access, there is no one open-access 
publishing model.  In addition to the pure open-access 
journals, the principles of open access are being 
implemented in journals that provide open access 
to some articles and not others (hybrid open-access 
journals), or that provide open access after some delay 
following publication (delayed open-access journals).  
Open-access principles are also being furthered in 
diﬀ erent forms in blogs, wikis, e-books, listserves, and 
ﬁ le-sharing systems.  An Autism Wiki, for example, 
managed by adults with autism and Asperger’s syn-
drome, publishes information on autism and related 
conditions.125 
Th ere are also many economic models being proposed 
to support open-access publishing.126  Th e most com-
mon funding model is that of the author paying the 
journal the cost of publication.  Fee waivers would 
be possible for those unable to pay.  Wellcome Trust 
advocates a variant of the “author-pays” model, under 
which the funding organization would pay for publica-
tion with disclosure/publication being considered as 
simply another phase of the research project.127  
It is not yet clear whether incorporating the cost of 
disclosure/publication into research grants would, as 
critics charge, reduce the total amount of research that 
is supported in the long run; running PubMedCentral 
costs NIH approximately 0.02 percent of its budget.  
But it is possible that if NIH grant budgets were 
declining, adding even small amounts of publication 
costs into grant budgets might cumulatively reduce the 
number of NIH grants.  
Other models include foundation support, advertiser 
support, and subscription support by research-oriented 
institutions, which would allow researchers from the 
subscribing institution to publish in the journal—a 
form of “co-op” journal.128   Another model would have 
commercial entities charged for access while maintain-
ing open access for not-for-proﬁ t entities and inde-
pendent researchers.  Like the open-source software 
community, the open-access publishing community is 
exploring a wide range of activities to support its mis-
sion, ranging from print sales and value-added research 
services to the conduct of related conferences and the 
establishment of electronic marketplaces.
Among the many unknowns about the relatively 
new area of open-access publishing is whether any of 
these models are economically sustainable.  Th ere are 
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conﬂ icting analytic studies.  Th e Wellcome Trust, a 
long-time open-access champion, commissioned several 
studies that showed that open-access publishing was 
30 percent cheaper than traditional publishing.129 
Indeed, most open-access publishers have reduced 
costs by embracing “lean-publishing” methods and free 
open-source publishing tools.130  Traditional publishers 
have countered with other studies showing that open-
access publishing is at least as costly, if not more so, 
than traditional publishing.  Elsevier has argued that 
higher education in the United Kingdom would have 
to pay 30 percent to 50 percent more to cover the costs 
imposed by author-pays publishing models, given the 
growth of research.131  Th ese disputes about sustain-
ability are likely to be resolved only by the passage of 
time.
Another argument raised against open-access publish-
ing is that it will eventually reduce the volume of 
research as publishers, particularly learned societies, 
will reduce or eliminate their publishing activities.  
Many learned societies depend on journals to support 
their other activities and might be forced to ﬁ nd other 
revenue streams or cut back their activities.   Whether 
competition from open-access journals will force the 
closing of these journals is yet to be seen.  But research 
good enough to be published in learned-society 
journals seems likely to ﬁ nd a place in new journals or 
expanded old journals, open access or not.
Openness and Academic Advancement
A more important issue today may be that of prestige.  
For academic researchers, many rewards—appoint-
ments, promotions, tenure, access to research support, 
reputation within their scholarly community—depend 
on publication.  Th e greatest rewards usually go to 
those who publish in the most prestigious journals.  
While academic researchers may support the goal of 
advancing science and may obtain personal satisfaction 
from working collaboratively with their peers, they 
understand the realities of academic advancement.  
Th ey realize they are competing with others for future 
publication glory and, like all of us, want recognition of 
their work.132 
Some academics, particularly more junior ones, may 
well be concerned with the eﬀ ect of publication in an 
open-access journal (as opposed to a traditional one) 
on their career prospects.  Will some peer-reviewed, 
open-access journals (such as those of PLoS) achieve 
the prestige of Nature or Science?133  Will they be 
shown to have a high impact in their ﬁ eld?  How will 
tenure committees, made up of senior academics (who 
may play major roles in learned societies), react to a 
colleague’s choice to publish in an open-access journal?  
Will new models of recognition for scholarship—
based on the number of citations, number of times 
downloaded, BioMed Central’s “most viewed” designa-
tion, or the amount of data generated or annotated—
begin to substitute for more traditional methods of 
judging an article’s worth?  Will scholarly journals 
and tenure committees give recognition to work in 
database science which utilizes immediate web posting 
of data? (Currently researchers who immediately post 
their results must forego traditional publishing because 
traditional journals generally do not accept already-
disclosed work.)  
Arti Rai, who has written widely on the issues sur-
rounding open science, has suggested that a major 
step forward would be for a prestigious peer-reviewed 
journal in the biomedical arena to confront the issue 
of academic competition by committing not to dis-
criminate against articles analyzing data already made 
publicly available.134 
Traditional Publishers Respond to New Open 
Models
Traditional journals have responded in diﬀ ering ways 
to the new open-access models.  Some are becoming 
open-access hybrids, providing authors, whom they 
would otherwise have published under traditional 
rules, with the option to pay the cost of publication 
and eliminate any period of exclusivity.135  Some, 
such as Nature, and publishers Blackwells, Oxford 
University, and Springer, have shortened the period of 
exclusivity that they impose, sometimes to as little as 
six months. 
Even six months may be conservative.  In 2001, the 
American Society for Cell Biology began providing 
free access to all articles published in their journal, 
Molecular Biology of the Cell, two months after initial 
release based on an analysis that showed that the ﬁ rst 
two months were the critical period for citations of the 
article, and thus should be the period of exclusivity.136
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Other traditional publishers are actively hostile to the 
open-access publishing model and appear committed 
to ﬁ ghting it—even for publicly funded research.  As 
one publishing executive noted “We’re like a ﬁ rm under 
siege.”137  An article in Nature.com, quoting from the 
minutes of a meeting of a committee of the American 
Association of Publishers (AAP), noted that AAP 
members need to pay special attention to PubMed 
Central, whose work “threatens our livelihoods.”138  It 
was suggested that members should raise the issue 
of censorship against PubMed Central.  “When any 
government funding agency houses and disseminates 
for public consumption only the work it itself funds, 
that constitutes a form of selection and self promotion 
of that entity’s interests.”139 
Such a response implies that we must choose between 
open-access and closed-proprietary models.  Th is is not 
the case. Th ere are many diﬀ erent models that occupy 
disparate places along the broad continuum of “open-
ness.”  As Paul David has written: “Considered at the 
macro-level, open science and commercially oriented 
R&D based upon proprietary information constitute 
complementary sub-systems.  Th e public-policy 
problem, consequently, is to keep the two sub-systems 
in proper balance by public funding of ‘open-science’ 
research, and by checking the excessive intrusions of 
claims to private property rights over material that 
would otherwise remain in the public domain of 
scientiﬁ c data and information.”140 
The Future of Open Publishing and Disclosure
In the coming years open access may well continue 
to pressure more-traditional models.  More institu-
tions are following MIT’s lead and creating digital 
archives.141  Proponents of open access are attempting 
to educate their academic colleagues about their 
intellectual property rights and the opportunities to 
provide access to their works; Science Commons is 
attempting to create a system by which authors can 
easily modify traditional copyright transfer agree-
ments to ensure that they retain suﬃ  cient IP rights to 
archive their works.142  Whether academic institutions 
ever adopt Stevan Harnad’s suggestion to mandate 
self-archiving—“Publish or perish, self-archive to 
ﬂ ourish”—it is likely that we will see new models 
emerging to provide greater openness.143  Harnad him-
self supports self archiving of even “closed materials” if 
meta-data—subject, author etc.—are made accessible 
through bibliographic databases so that others can 
learn of the works.  
Both open access and traditional journals can be more 
open by being more rigorous in ensuring that authors 
disclose potential conﬂ icts of interest.  Similarly, both 
open access and traditional journals should expand the 
availability of standardized data that can be aggre-
gated, searched, and manipulated. 
Finally, whether research results are disclosed through 
traditional or open-access publication, or via archiving, 
the time interval between disclosure and incorpora-
tion into clinical-treatment regimens is tragically 
long.  According to research cited by the Agency for 
Healthcare and Quality Research and the National 
Cancer Institute, it takes from 13-17 years to get 
14 percent of research into healthcare practice.144  
Th ose who study, fund, and utilize healthcare-related 
research need to identify and address the problems 
inhibiting the dissemination of research results and 
their implementation in treatments.145  To continually 
improve healthcare we will need to ensure that the 
extraordinary discoveries of creative researchers do not 
remain “academic” but rather reach those in need more 
quickly.  
Recommendations Regarding Openness and 
Publishing and Disclosure of Research Results 
Th e explicit policy of the federal government should 
be to promote the broadest possible access to research 
results in the healthcare arena, particularly govern-
ment-supported research.
Th e principles of the proposed Federal Research Public 
Access Act should be enacted into law.
Th e federal government should not discriminate 
among models for publication/disclosure.
Th ose federal agencies supporting research should 
positively respond to requests for funding to pay for 
publication/disclosure of sponsored research.
In evaluating applicants for research funding, federal 
agencies supporting research should recognize the 
scientiﬁ c value of database science and scholarly work 
that may be validated by means other than traditional 
scholarly publication.
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Federal agencies supporting research should require 
that sponsored researchers disclose potential conﬂ icts 
of interest in any publications/disclosure of the spon-
sored research.
Federal agencies supporting research should target 
eﬀ orts to reduce the interval between publication/dis-
closure of research and its implementation in accepted 
treatment regimes.
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The Vision of Electronic Health Records
Over the last decade the United States has been lurch-
ing toward implementing a system of electronic health 
records (EHRs).  What is being sought in the EHR 
would not merely replicate, in electronic form, today’s 
patient record, but could include, in addition to the 
individual’s medical history, other information such as 
his or her family medical history, as well as genomic, 
pharmacogenomic, and nutrigenomic data, environ-
mental exposures, dietary and exercise practices etc.  It 
would be the key to “empower individual patients to 
assume a much more active, controlling role in their 
own health care; improve access to timely, eﬀ ective, 
and convenient care; improve patient compliance with 
clinician guidance; enable continuous monitoring of 
patient conditions by care professionals/care teams; 
and enable care providers to integrate critical informa-
tion streams to improve patient-centered care, as well 
as to analyze, control, and optimize the performance of 
care teams.”146 
From the standpoint of openness the EHR would 
be a major step forward in both accessibility and 
responsiveness.  Th e Health Insurance Portability 
and Accountability Act (HIPAA) today guarantees a 
patient the right to access his or her records, although 
anecdotal evidence suggests that it is a right that is 
rarely invoked.147  Ideally, the EHR would be easily 
available and more valuable, with electronic access for 
patients and other authorized users anytime and any-
where.  It would be far more responsive than today’s 
medical record,  capable of electronically receiving data 
regarding treatments, lab results,  hospital-discharge 
information, prescription records etc. from any 
authorized user who deals with the patient anywhere 
and anytime.  And it could arguably be made more 
secure with greater protections for patient privacy 
than today’s paper records, which do not seem to be 
easily protected from the gaze of those interested, for 
example, in a celebrity’s medical status.148
Having access to more complete and accurate informa-
tion would allow caregivers to oﬀ er better and more 
personalized treatment; HHS data show, for example, 
that one-seventh of primary-care visits are aﬀ ected 
by missing data.149  Th e improvement in data access 
would be particularly marked if the patient moved, or 
if the patient’s records were physically destroyed, or if 
the patient came to an emergency facility that had not 
previously provided treatment, or if the patient were 
comatose —in the aftermath of Hurricane Katrina all 
of these conditions might have been simultaneously 
met for a single patient.  An EHR would be extremely 
useful when a patient is being treated by multiple 
healthcare providers for multiple ailments and when 
healthcare information is scattered across multiple 
facilities—which is often the case for chronically ill 
patients who generate a disproportionately large pro-
portion of healthcare costs.  It would, if comprehensive 
and accurate, help avoid duplicative testing, conﬂ icting 
prescriptions, and redundant treatments.  It could, as 
one observer put it, improve a caregiver’s ability to deal 
with misinformation, missing information, mishandled 
information, mislabeled information, and misﬁ led 
information.150  
An EHR could serve as a platform for writing pre-
scriptions and having them ﬁ lled, ordering tests, sched-
uling appointments, providing reminders, and issuing 
alerts.151  By recording prescriptions and reactions 
it could provide useful inputs for an expanded FDA 
post-authorization surveillance system.  And having 
data in standardized electronic form could potentially 
reduce health spending.  RAND researchers estimate 
that EHR implementation costs could total $8 billion 
per year over 15 years.152  But the same RAND study 
predicts that annual savings from health IT would 
average $81 billion over 15 years.153  HHS estimates 
that the widespread adoption of EHRs could reduce 
health spending by 7.5 percent to 30 percent, and 
further cut administrative costs, which constitute one-
third of all healthcare expenses.154  (Because an EHR 
would be created, maintained, and utilized by real and 
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fallible people, the chance that it would completely 
fulﬁ ll all these goals approaches zero—but it oﬀ ers the 
opportunity for enormous advances.) 
The Reality of Electronic Health Records
EHRs might be characterized today as an extremely 
slowly developing success story.  In 2004 President 
Bush set a goal of having an electronic medical record 
for every American in 10 years—by 2014.155  At 
present only a quarter of U.S. doctors utilize electronic 
records although that is a 30 percent increase from 
2001 (By contrast 98 percent of physicians in the 
Netherlands utilize electronic records, 92 percent in 
New Zealand, and 89 percent in the United Kingdom.  
Th ese electronic records, however, do not necessarily 
have all the characteristics of the EHRs described 
above.) 156 
In early 2007 four HHS-funded prototype electronic-
records systems linking healthcare systems from 
around the country were showcased in Washington.157 
At almost the same time a consortium of employers 
led by Wal-Mart and Intel announced that it would 
establish an EHR system managed by a not-for-proﬁ t 
third party and covering their 2.5 million employees 
who would be given control over access to information 
about themselves.158  Th e Veterans’ Administration, 
acknowledged as the government leader in EHRs, is 
rolling out MyHealtheVet, a system for its 7.6 million 
enrollees, which will gradually be extended to include 
treatment records, appointments, chemical and blood 
tests, allergies and immunizations, and hospital 
discharge records; the Department of Defense and the 
Veterans’ Administration have agreed to a process for 
a seamless real-time exchange of data between them-
selves, although completion of this process is many 
years away.159  IBM and the Mayo Clinic are collabo-
rating on a system for the Clinic’s 4.4 million records 
which will include personal histories, imaging, tissue 
analyses, as well as biochemical and genetic data.160 
Th ere are a number of major obstacles to the at-
tainment of the EHR vision.  Th e balkanization of 
healthcare has resulted in very diverse participants 
using many diﬀ erent legacy systems with few areas 
of consistency across the country.  Attempts to share 
information between diﬀ erent systems now produce 
a mosaic with too many missing pieces, as diﬀ erent 
systems utilize diﬀ erent standards and procedures and 
are not designed to be interoperable.   
Moreover, any major information technology project 
can be daunting and contains some risk of failure.  A 
series in the Los Angeles Times demonstrated how 
even leading healthcare organizations such as Kaiser 
Permanente, which have embraced information and 
communications technology, are struggling to over-
come technical problems in accomplishing their EHR 
goals.161 
Th e lowest take-up rate for EHRs is in physician’s 
oﬃ  ces consisting of one or two physicians—and 50 
percent of U.S. physicians practice in such settings.162  
Th e use of information technology in these practices, 
beyond billing and lab-based tests, is not a matter of 
course.163 
Th ere are few clear incentives for a small medical prac-
tice to convert its records.  It would bear the relatively 
high costs—researchers estimate a cost of $33,000 
per physician to adopt EHRs—but the real beneﬁ ts 
would go to the healthcare system as a whole.164  Th ere 
is a need to demonstrate real gains in results and 
eﬃ  ciency to caregivers, particularly if the most im-
mediate impacts may be from fewer patient visits and 
fewer authorized tests.  Even major institutions that 
are already beneﬁ ting from the improvements made 
possible by the use of EHRs may be reluctant to share 
data if sharing increases the likelihood that they will 
lose patients.
While the cost of establishing an EHR system is 
high, there is no ready source of funding for the eﬀ ort.  
One regulatory step, permitting hospitals to donate 
medical-record systems to physician practices, has been 
taken.165  Various bills have been introduced in the 
Congress to address the cost issue by means such as 
grants and loans to smaller medical practices, increas-
ing depreciation rates for health IT investments, and 
bonuses for those connecting and providing Medicaid 
reporting electronically.166
Several innovative responses are already addressing the 
cost issue.  On the local level, New York City is plan-
ning to provide free software to 1500 large and small 
practices that have a substantial percentage of Medic-
aid eligible patients.167  On a larger scale, the National 
E-Prescribing Patient Safety Initiative is oﬀ ering “free 
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electronic prescribing software to every physician in 
the United States.”168  World VISTA, an open-source 
software system for EHRs, modeled on the Veterans 
Administration’s VISTA patient-record system, has 
been created and is available to all.169  It appears likely, 
however, that further ﬁ nancial incentives to encourage 
and support adoption of EHRs will be necessary to 
meet the 2014 goal; even with such incentives there 
is virtually no chance that all existing records will be 
converted due to the cost and the quality of the records 
themselves.170  
Two additional obstacles to the establishment of an 
interoperable national EHR system are the lack of 
standards necessary for interoperability, and the lack 
of agreement on how to achieve acceptable levels of 
privacy and security.
Standards
A broadly based, joint public-private eﬀ ort, led 
by HHS, is attempting to develop the necessary 
standards to allow data in one part of the healthcare 
system, when authorized, to be available for access for 
clinical, administrative, payment and research pur-
poses.  Standards would cover how the messages that 
update the EHR would be sent and accepted as well as 
the content of the messages.171  Th e present schedule 
for standards development calls for this work to be 
completed by 2008.172 
Th ere is some dispute over the progress of the stan-
dards development process which, even under the very 
best of circumstances, would be diﬃ  cult, given the 
number of standards involved and the fragmentation 
of the healthcare industry.  Compounding the problem 
are the myriad disputes over intellectual property that 
competing vendors would like to have included as part 
of the standards.
One small but illustrative example: Th ere are three 
proprietary systems for describing allergenic reactions 
to penicillin.  It would obviously be preferable to 
choose one system so that data on allergenic reactions 
to penicillin can be fed into the EHR in a standardized 
format, but in a consensus-based process this is not 
always easy—and the 2008 deadline for this standard 
is looming.  Even if one proprietary system is chosen, 
issues might arise over royalties.173  To keep the 
standards-development process on track, the federal 
government will have to play a major role; as the party 
that pays roughly half of the healthcare costs in the 
United States, it can exercise enormous leverage should 
it choose to do so or if it is perceived as willing to do so.
Technology will also surely play an important role in 
facilitating interoperability.  For example, just as the 
Extensible Business Reporting Language (XBRL) 
www.xbrl.org, was developed for ﬁ nancial reporting 
purposes, new languages may provide semantic harmo-
nization of the many legacy systems that today exist in 
the healthcare sector.174 
Privacy and Security
Probably the most contentious issue is the impact of 
EHRs on patient privacy—an area where total open-
ness is certainly not the goal.  We need thoughtful 
eﬀ orts to reconcile the beneﬁ ts of openness made 
possible by an eﬀ ective EHR system with the require-
ment that we close the system by restricting access 
suﬃ  ciently to protect privacy.  Th e EHRs of the future 
that we have been describing would raise the stakes 
for privacy and security solutions dramatically, as they 
would vastly increase the amount and kinds of sensitive 
data available. 
Studies by the Markle, Pew, and California Health 
Foundations have shown that while most Americans 
are enthusiastic about improving how their healthcare 
information is shared among their caregivers, they 
are concerned about the potential for abuse of privacy 
regarding that information.175  Underlying that con-
cern is the belief that the leak of a patient’s medical 
condition or genomic attributes or other sensitive 
information could result in great harm to the patient 
including loss of employment, loss of access to insur-
ance, or other possibly irrevocable consequences.176  
(For similar reasons, few Americans, for example, have 
expressed a willingness to undergo genetic testing.  
Th is may change given the broad bipartisan support in 
Congress and the White House for legislation forbid-
ding discrimination based on genetic information.  
Some prominent individuals are, however, already 
making their genetic proﬁ les public.)177 
Unauthorized disclosure may also increase the growing 
problem of “medical identity theft”  (called the most 
underreported and poorly documented of identity 
crimes) spurred by the high cost of medical care 
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and the large number of uninsured or underinsured 
people.178   Victims of medical identify theft may not 
only be charged for someone else’s treatment, exposed 
to inappropriate treatment based on medical records 
that reﬂ ect another person’s medical condition, but 
also may face the loss of their own health insurance.179   
Th ey may wind up with mixed records including 
information about themselves as well as somebody else. 
All stakeholders in the eﬀ orts to create an interoper-
able national EHR system stress their commitment 
to protecting the privacy and security of the system.  
Th e Acting Coordinator of Health Information Policy 
has emphasized the Administration’s commitment in 
calling for a system that would give “people the capabil-
ity to decide how they view, store and control access to 
their own information.  A person could say how that 
information ﬂ ows to speciﬁ c entities or completely 
block the ﬂ ow of information.”180   
But a gap exists between the professions of commit-
ment and the eﬀ orts required for the diﬃ  cult task 
of creating and implementing generally acceptable 
privacy and security protections.  Th e Government 
Accountability Oﬃ  ce has been highly critical of the 
Administration’s privacy eﬀ orts.181  Th e chair of a 
panel providing advice to HHS on health-information 
policy accused the Administration of lacking “a sense 
of urgency” about privacy and resigned.182 
Today’s National Healthcare Privacy 
Law—HIPAA 
HIPAA is the controlling federal law governing the 
privacy and security of patient medical records.  Th ere 
are many additional laws at the state level which reﬂ ect 
varying levels of privacy protection.  (Th e patchwork 
nature of these laws serves as an additional barrier to 
the implementation of an interoperable national EHR 
system.) 
Th e application of current HIPAA regulations, which 
took several years to draft and were quite contentious, 
is not acceptable to many stakeholders.  For example, 
HIPAA does not cover many parties likely to have 
access to EHRs.183  Th e American Health Information 
Community’s “Conﬁ dentiality, Privacy and Security 
Workgroup” has recommended that every party that 
participates in an electronic health-information ex-
change of individually identiﬁ able health information 
be subject to enforceable privacy and security criteria 
at least equivalent to the relevant HIPAA require-
ments.184  Th e National Committee on Vital and 
Health Statistics has made a similar recommendation 
regarding any entity that creates, stores, transmits or 
uses personally identiﬁ able health information.185 
Th ere is, moreover, considerable skepticism about 
the enforcement of even current rules. Over thirty 
thousand complaints have been ﬁ led pursuant to the 
regulations, but there have been few enforcement 
actions and fewer sanctions imposed.186  Th ousands of 
complaints remain unresolved.187 
According to a recent CIO Magazine survey, only 39 
percent of companies surveyed believed that they were 
fully HIPAA compliant; the survey showed that, on 
the whole, HIPAA compliance today is lower than in 
earlier years.188  Another poll showed that three out of 
ﬁ ve people interviewed do not trust HIPAA to protect 
their privacy.189 
Recent Privacy Initiatives
An enormous amount of work has been done over 
the last ﬁ ve years to try to resolve issues of healthcare 
privacy and security.  Th e Markle Foundation has 
led a group of over 100 organizations in an eﬀ ort 
over the past several years to develop a “Com-
mon Framework”—a set of technical and policy 
standards—for health information exchange.190  
Health information, under this “federated” model, 
would remain under control of the parties that collect 
it, leaving judgments about who should and should not 
see patient data in the hands of the patient, the physi-
cians, and the institutions that are directly involved 
in providing treatment.  Th is federated model aims 
to avoid a large, centralized database which might be 
more vulnerable to privacy and security breaches.  Th e 
system would be based on common, open technical and 
policy standards that could work with existing hard-
ware and software, and would rely on model business 
contracts to govern the exchange among organizations 
holding the data.191  It would support variation and 
innovation to respond to local needs and would contain 
feedback mechanisms to ﬁ x faulty data.
Central to the Common Framework is a set of prin-
ciples to protect privacy and security that would be 
embodied in the technology.  Th ese principles are: 
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• Openness and Transparency: Individuals should be 
able to know what information exists about them, 
where it is, and who can access it;
• Purpose Speciﬁ cation and Minimization: Th e 
purposes for which information is collected should 
be speciﬁ ed when it is collected.  Subsequent use 
should be limited to those purposes, or if used for 
other purposes, those purposes must be speciﬁ ed; 
• Collection Limitation: Personal health information 
should only be collected for the speciﬁ ed purposes, 
by lawful and fair means, and where possible, with 
the knowledge or consent of the data subject;
• Use Limitation: Personal data should not be 
disclosed or otherwise made available for purposes 
other than those speciﬁ ed;
• Individual Participation and Control: Individuals 
should control access to their personal informa-
tion.  Th ey should be able to obtain a response 
from any entity that controls personal health 
information about whether that entity has per-
sonal health information about them.  Th ey should 
be able to obtain that information in a reasonable 
time in an understandable form for a reasonable 
price. Th ey should be able to have that information 
amended.  Th ey should be able to appeal denial of 
access;
• Data Integrity and Quality: Personal data that is 
collected should be relevant to the purposes speci-
ﬁ ed, current, complete, and accurate;
• Security Safeguards and Controls: Personal data 
should be protected by reasonable security safe-
guards against such risks as loss or unauthorized 
access, destruction, use, modiﬁ cation or disclosure;
• Accountability and Oversight:  Entities in control of 
personal health data must be held accountable for 
implementing these principles;
• Remedies: Legal and ﬁ nancial remedies must exist 
for security breaches or privacy violations.192
Th ese principles would provide a sound basis for an 
EHR system.  Th ey put the focus clearly on the patient 
and his or her role in controlling access. Although 
they do not deﬁ nitively establish who “owns” personal 
health information, they would establish obligations 
for any entity that collects such information, and 
would leave data collections decentralized.  Th ey 
provide for data minimization and cleansing, auditing 
of data use, as well as remedies for breaches of privacy 
and security.  
But agreement on principles still leaves many diﬃ  cult 
issues to be resolved.  Rules must be developed about 
who is allowed to have access to what information and 
under what conditions.  Th en the system must be able 
to verify that the party requesting access is authorized 
to have access, and can be identiﬁ ed and authenticated 
as the appropriately authorized party.193  Th ese au-
thorization, identiﬁ cation, and authentication issues 
are being addressed in other domains that deal with 
sensitive information, such as banking and ﬁ nance and 
homeland security; healthcare will surely beneﬁ t from 
eﬀ orts to ﬁ nd answers in other sensitive areas. 
Th ere are obviously a myriad of other questions 
that will have to be decided.  Will there be national 
standards for privacy and security preempting state 
rules or will national standards create baselines for 
privacy and security protections?  How will the system 
deal with circumstances that do not readily allow a 
patient to authorize access to information?  (Studies 
on how to improve emergency care show how conten-
tious issues of consent can be.)  What, if any, are the 
appropriate limits on patient control of access?  How 
will exceptions be dealt with?  How will disputes be 
resolved?  How will the system be structured so that 
the patient-centered processes for controlling access to 
information do not impede the delivery of services—so 
that practitioners, wary of anything that gets in the 
way of their providing quality patient care, will not 
reject or undercut the system?  How will public health 
needs, such as in the case of a pandemic, be balanced 
against patient privacy rights?  What will be done in 
the case of unauthorized access to patient informa-
tion?  Will patients be able to opt out of the system, 
or will the system, as one leading expert suggests, gain 
support by requiring that patient’s opt-in?194  And 
given researchers’ concerns (it has been argued that 
the famous Framingham Heart Study could not be 
conducted now under today’s less rigorous HIPAA 
regime), will a system designed to protect patient 
privacy be ﬂ exible enough to allow the use of EHRs for 
research purposes?  Th e questions go on and on.
And even if we feel conﬁ dent that the major ques-
tions have been answered, there are very substantial 
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challenges to implementation.  For example, the 
business contracts between organizations that the 
Common Framework foresees as necessary for the 
exchange of information are not in place and will not 
come into being without great eﬀ ort.  Much of the data 
that exists in today’s records are inaccurate and should 
be corrected but it is easier and cheaper to avoid cleans-
ing records; much information is missing and will be 
expensive and time consuming to ﬁ x.  Th ere is little 
evidence that suﬃ  cient resources and commitment will 
be available to enforce new privacy and security rules.
However great the diﬃ  culties, if EHRs are likely to 
provide the beneﬁ ts described earlier, we should be 
able to ﬁ nd solutions.  We must recognize that no 
system is born perfect or ever achieves perfection, but 
any EHR system must have the capacity to evolve.  
No massive system for exchanging information exists 
that will guarantee absolute conﬁ dentiality. Th ere 
will be violations and breakdowns, so there must be 
strong provisions to protect privacy and eﬃ  cient and 
eﬀ ective mechanisms to deal with violations.  Patients 
and practitioners alike must feel conﬁ dent that their 
interests are adequately reﬂ ected in the rules; both 
must feel that the beneﬁ ts outweigh the costs. 
Andy Grove, formerly of Intel, has predicted that the 
United States will transform its healthcare system 
through the use of information and communications 
technology as has occurred in other sectors of the 
economy, “only after the next pandemic.”  To prove 
him wrong and bring an interoperable, nationwide, 
eﬃ  cient, patient-centered, and privacy-respecting EHR 
system to fruition will require a strong commitment 
by the federal government with its role in healthcare-
funding and national perspective.
Electronic Health Records and the 
Development of Evidence-Based Medicine
EHRs are important in their own right, being the key 
to personalized patient treatment.  EHRs are also 
likely to play an important role in monitoring drug 
safety.  But perhaps their greatest potential lies in fur-
thering the development of evidence-based medicine.  
Little hard evidence exists to demonstrate that many 
of today’s medical treatments are based on reliable 
data.195  As the Institute of Medicine described it, we 
face a “structural inability of evidence to keep pace 
with the need for better information to guide clinical 
decision making.”196  Clinical trials, as we have seen, 
provide such data but they are expensive, time consum-
ing, limited in scope and “fraught with questions of 
generalizability.”197 
We can do better.  Imagine if we were able to construct 
collections of appropriately de-identiﬁ ed EHRs that 
have been bulked up with genomic, pharmacogenomic, 
proteonomic, epigenomic, and nutrigenomic data, 
supplemented with environmental-exposure infor-
mation, diet and exercise data, and family medical 
histories.  What if we added insurance claims data and 
the data underlying clinical trials and research funded 
by governmental agencies?  
Building such databases, providing appropriate ac-
cess, (perhaps in some cases limited to professional 
researchers as opposed to anyone and everyone), and 
ensuring privacy and security are, of course, not easy 
tasks.  Some goals may not be achievable, such as 
a perfectly de-identiﬁ ed system.  (Th e inadvertent 
disclosure of supposedly de-identiﬁ ed AOL search 
data and the relatively quick identiﬁ cation of AOL 
users illustrate the diﬃ  culties.)  Some goals remain in 
tension; researchers generally prefer more information 
to be available for correlation in developing clinical 
guidelines while privacy advocates generally prefer less.
But around the world we are seeing important steps 
forward.  In Europe, Asia, and the United States, 
researchers are recruiting hundreds of thousands of 
people to participate in biobank initiatives that compile 
an individual’s genetic, health and lifestyle informa-
tion, and track it over time through electronic health 
records.198  Biobanks seek to better understand the 
linkages between these and other factors to improve 
the prevention and treatment of myriad disabling and 
life-threatening diseases—including cancer, heart 
diseases, diabetes, arthritis and types of dementia. 
Biobanks are not a new phenomenon, although these 
biobanks aren’t your grandfather’s or even your father’s 
biobanks.  (Fifty years ago, Sir Richard Doll followed 
the health of 50,000 doctors and ultimately unveiled 
the link between smoking and lung cancer.)199 
But for all of the possibilities to prevent and cure 
disease, biobanks remain controversial.  Some medical 
experts worry that “volunteers will be asked to donate 
their DNA without really knowing how it’s to be 
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used or who’s going to use it.”200  Others worry about 
whether private companies will be permitted access 
to the sensitive data.201  And these worries say noth-
ing of the technical hurdles that computer scientists 
must overcome to ensure that the data generated by 
biobanks can be structured to respond to queries 
that may change in unexpected ways over time.  How 
these issues are resolved will undoubtedly shape the 
direction of biomedicine and the healthcare industry 
generally, for years to come. 
Beyond these new biobanks, sponsored by govern-
ments and not-for-proﬁ ts such as the American Cancer 
Society, there are existing data collections which are 
being used in new ways.  While they contain only a 
small portion of the possible data sources, even at this 
early stage they provide a far richer data environment 
than even the best clinical trials.  Both the VA and 
Kaiser-Permanente, with roughly 8 million patient 
records apiece, have patient-record collections includ-
ing more cancer patients than have participated in all 
the cancer clinical trials ever conducted.202 
As part of its Research Program on Genes, Environ-
ment and Health, Kaiser’s Northern California 
Division is sending a detailed survey to each of its two 
million adult subscribers asking for information on 
their habits and family medical histories.203 (Th e risk 
that a woman will develop breast cancer, for example, 
is inextricably linked to family medical histories.) 204  A 
year from now Kaiser plans to solicit genetic samples 
from its patients to test and add to their records.205  
Kaiser’s long-term vision, similar to that of the VA, 
the Mayo Clinic, and others, is to use its vast record 
holdings to determine the optimal treatment regime 
for each patient.  A consortium of health insurance 
providers and several medical-practice associations are 
exploring collaborations to the same end.206 
While such eﬀ orts are dominated by large groups, 
even sophisticated smaller institutions are moving in 
the same direction.  Geisinger Health, for example, 
is attempting to utilize its relatively stable patient 
population in central Pennsylvania to build a database 
rich in extended-family histories, and is supplementing 
these with U.S. Geological Survey data on local water 
supplies to determine environmental exposures.207 
Large-cohort studies can usefully supplement other da-
tabases, such as those from clinical trials that may not 
be representative of the U.S. population.  Some cohort 
studies of women and children, traditionally funded by 
the federal government, were cut back in recent years 
because of budget pressures.  Th e announcement in the 
fall of 2007 of a National Children’s Study targeting 
100,000 children from birth to age 21 by the National 
Institute of Child Health and Human Development of 
the NIH is therefore very good news.
Th ink of what we could learn if researchers could have 
access to all this information.  Not only would we be 
able to personalize treatments and monitor drug safety, 
but we could be increasingly conﬁ dent that recom-
mended treatments actually are based on evidence, 
not anecdote or habit.  As more data are added, and as 
data mining improves, researchers will be able to create 
predictive models and test these against the aggregated 
data and through better-targeted clinical trials.  We 
will also be better able to compare the eﬃ  cacy of vari-
ous interventions which we do all too little today.
Perhaps in no other sector of the economy do we spend 
so little eﬀ ort to measure and improve performance.  
HHS’s Agency for Healthcare Research and Quality 
has a relatively small budget of $500 million to con-
duct studies of comparative eﬀ ectiveness of procedures. 
But comparing this $500 million with the $2 trillion 
dollars in healthcare expenditures (0.025 percent) 
validates what one noted physician author has writ-
ten: “Th e scientiﬁ c eﬀ ort to improve performance in 
medicine—an eﬀ ort that gets only a pitifully miniscule 
portion of scientiﬁ c budgets—can arguably save more 
lives in the next decade” than all the basic break-
throughs that we hear about in the news.208 
Eventually we will be able to identify and extract the 
right data.  Eventually we will be able to perform the 
right comparisons.  Eventually we will ﬁ nd the right 
balance between eﬃ  cient, standardized care which 
serves most patients well, and individualized treat-
ments based on less common attributes in a patient 
which is likely to be much more expensive.209   In the 
future we might, for example, see fewer blockbuster 
drugs—like any other manufacturer, a pharmaceutical 
company searches for a product useful for the largest 
possible group in order to maximize revenues and 
amortize costs over the largest number of users—and 
more targeted therapeutic regimens. (But the individu-
alized pill is likely to remain an expensive and distant 
dream.210) 
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Th e mining of these databases should continually gen-
erate new clinical best practices.  Th ere are hundreds 
of guidelines already in the Agency for Healthcare 
Research and Quality’s Guidelines Clearinghouse but 
with over 10,000 various medical conditions we still 
have a long way to go.211  And we still need to ensure 
that those clinical best practices inform the work of 
clinicians.  Without eﬀ ective monitoring and rewards 
for their use, however, they will be an empty tribute to 
our ability to gather and manipulate data.  We would 
have demonstrated that access to information is not 
suﬃ  cient, but that improved healthcare will result only 
if we incorporate our more sophisticated understand-
ings into real world actions. 
Th e issue of potential conﬂ icts of interest is particu-
larly acute when recommended-treatment regimes are 
being created.  Th ese regimes should be based solely on 
the best possible scientiﬁ c information.  Any potential 
for the skewing of these recommendations based on 
ﬁ nancial interest must be avoided.  Strenuous eﬀ orts 
should be made to ensure that participants in the 
process are not subject to potential conﬂ icts and strict 
disclosure requirements should be in eﬀ ect. 
Recommendations Regarding Electronic 
Health Records and the Development of 
Evidence-Based Medicine
Th e federal eﬀ ort to develop standards for an interop-
erable, national EHR System should be given high 
priority and suﬃ  cient support, including a strong com-
mitment by the federal government to use its leverage 
to obtain timely agreement on standards.  Legislation 
should promote the establishment of national health 
data standards and an interoperable national EHR 
system. 
Individuals and groups providing and funding 
healthcare should institute appropriate incentives for 
the adoption of information and communications 
technologies (including EHRs) to reduce healthcare’s 
burdensome administrative costs.
New rules designed to ensure the privacy and security 
of healthcare records must be adopted to provide 
assurance to patients and practitioners.  Th ese must 
cover all entities involved in the handling of indi-
vidually identiﬁ able health-related information.  Th e 
federal government must demonstrate a commitment 
to enforcement of these rules and provide suﬃ  cient 
funding to do so.
Th e federal research agencies should increase their 
support for the development of the very large databases 
necessary for progress toward evidence-based medicine 
including the necessary data standards.  Support 
should also be provided for research on how such data 
should be structured to facilitate the varying queries 
necessary to develop evidence-based clinical treatment 
practices, to compare the safety and eﬃ  cacy of various 
treatments, and to allow the development of predictive 
models of diseases and treatments.
Th e National Academy of Sciences should undertake 
a study of de-identiﬁ cation techniques that might be 
applied in the creation of large databases to protect 
the privacy of patients in order to provide guidance to 
federal policymakers. 
Strict requirements on the disclosure of conﬂ icts of 
interest should be applied to those participating in 
the development of recommended clinical practice 
regimens.
Congress should provide additional support for long-
term cohort research for groups underrepresented in 
existing biomedical research results.
HIPAA should be amended to require that those par-
ties who hold a patient’s medical records must provide 
the patient with the opportunity to receive copies of 
those records pursuant to HIPAA in digital form.212 
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Biomedical research and evidence-based medicine 
are cases where the increased access to information 
and the ability to manipulate data reveal the value 
of greater openness.  Th is Chapter will focus on the 
impact of providing more and better information to 
patients and caregivers, and being more responsive to 
the unique contributions they can make.
Th e kinds of openness described in this section—such 
as allowing patients to evaluate the interventions being 
tested on them in clinical trials or increased attentive-
ness by caregivers to patients’ stories—are not treated 
by economists as precisely the same as the openness 
that enhances the research process.  But they can be 
understood using the same characteristics of acces-
sibility and responsiveness described earlier, and can 
provide signiﬁ cant beneﬁ ts, particularly with regard to 
disease prevention and treatment. 
Changing Ideas About the Role of the Patient 
In the past, patients were often viewed as passive 
recipients of health-related information and treatment 
decisions from their caregiver.  Healthcare revolved 
around meetings between sick patients and their 
doctors; the patient’s role in the “production” of good 
health was basically to do what an oracular caregiver 
instructed.  Treatments were based on limited data 
and anecdotal evidence.  Patients were given few 
incentives and little training to take more responsibil-
ity for their own well being.  One did not look to the 
mainstream medical community for information on 
“lifestyle” choices. 
Today we live in a world of patient-centered healthcare. 
We are awash in information.  Increasingly, eﬀ orts are 
being made to encourage individuals to take greater 
responsibility for their own health and to make choices 
that reduce the likelihood of illness. 213  An advertise-
ment for Pﬁ zer sums it up: “Get well soon’?  We prefer, 
‘Stay healthier longer.”     
We have learned that the most important drivers of 
healthcare costs are chronic conditions and serious 
illnesses that may be prevented or mitigated by patient 
actions.214  Th erapeutic encounters between a sick 
patient and his or her trusted doctor do not dominate 
healthcare costs; as many of us have experienced, these 
encounters seem to get shorter and shorter and may 
involve doctors whom we have never seen before—or 
even no physician at all.215 
Under these conditions, how can openness improve a 
potential patient’s ability to prevent problems and to be 
a better partner in dealing with those that arise?
Patient Access to Healthcare Information  
Perhaps the greatest opportunities arise from the 
increased availability of healthcare-related information 
via the Internet, including information on prevention, 
exercise, and nutrition.  In 2006, ninety-ﬁ ve million 
Americans searched the web for information on 
speciﬁ c diseases, how to treat chronic illnesses, how to 
assess a speciﬁ c health risk, who or where to go to for 
help, or where to buy health-related products.216
Some of the information consumers get from the 
Web is right, some of it is wrong, and much of it is 
not suﬃ  ciently particularized to be of great value 
for an individual.217  (Here again the double-edged 
sword of openness is visible.  Much more information 
is available but we lack good tools for evaluation and 
there is too little transparency about the sources of 
the information.)  Th ere is a tremendous need for 
evidence-based, comprehensible, consumer-friendly, 
and relevant healthcare information and for quality 
measures to allow readers to make better judgments 
about information from the many players who would 
like to be their source for healthcare information.  
Th e government is playing a vital role, one that the 
National Library of Medicine (NLM), in particular, 
has embraced.218  Its MedLinePlus website provides 
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well-vetted information based on the most current 
scientiﬁ c data on everything from conditions such as 
arthritis and back pain to frequently asked healthcare 
questions.  NLM has consistently worked to make its 
healthcare information more accessible to individuals.  
Other governmental agencies also provide excellent 
sources of healthcare information.219 
Many valuable sources of information are sponsored 
by private-sector organizations.  Th e American Cancer 
Society and the American Heart Association for 
example, provide high-quality information related to 
the diseases that they ﬁ ght.  For-proﬁ t entities operate 
healthcare portals such as WebMD, Revolutionhealth-
care.com, Everydayhealth.com, and the HealthCentral 
Network.220  Microsoft recently purchased Medstory, 
Inc., a healthcare search engine for consumers, and 
in October of 2007 released HealthVault, a free and 
ad-supported portal that will allow individuals to 
download data from their caregivers or from digital 
devices such as glucometers, upload data on their diet 
and exercise routines, and share the encrypted data 
with others.221  Th e healthcare portals are all trying 
to diﬀ erentiate themselves with additional services—
displaying health tips, linking patients with insurers, 
rating medicines, doctors and hospitals and providing 
decision-support capabilities.  One can even get “sec-
ond opinions” via the Internet.222   
As is true in other areas, conﬂ icts of interest due to the 
role of advertisers or donors may aﬀ ect the healthcare 
information provided; patients can, however, ﬁ nd 
disinterested sources of information at government 
websites and those of groups such as Consumers 
Union or the Center for the Study of Services.223  
Patients themselves are likely to publish ratings of 
information sources on healthcare, just as they rate 
other goods and services oﬀ erings in today’s Web 2.0 
world.224 
Personal Health Records
Some healthcare portals (and many employers and 
insurers) are building infrastructures that allow an 
individual to create a web-based “personal health 
record” (PHR), an individual’s version of the EHR.  
PHRs are designed to be portable and under the 
control of the individual.  As with EHRs, certain other 
countries have made greater progress.  In Germany, for 
example, all patients carry their medical records on a 
single computer chip.225 
PHRs oﬀ er a potentially valuable resource for those 
individuals who choose to adopt them. Th ey include 
a wide variety of information such as medical history, 
present medications, the results of tests and remote 
monitoring, a patient’s reporting on his or her health, 
and current treatment regimens.226  Th ey hold out the 
promise that patients will change their behaviors if 
they have more convenient access to their records—
something that, unfortunately, does not always follow.
But there are signiﬁ cant obstacles to PHR develop-
ment. Healthcare-related entities are not required by 
HIPAA to supply information to patients in a digital 
format.  Standards for electronic data exchange are not 
yet resolved.  Concerns about privacy and security are 
also aﬀ ecting PHR take-up.227 
Other Sources of Information
Th e Internet allows access to another source of 
information—peer groups made up of individuals (or 
people related to them) who share an interest in the 
same medical condition.  Even more important for 
group participants than the information provided may 
be the sense of connection to others facing similar 
problems—others just like oneself.  Th e information 
and support are particularly helpful for patients with 
less-common conditions where an individual’s care-
giver may have encountered the condition rarely, if at 
all.  In one well-designed web-based group for suﬀ erers 
from rare carcinoid cancer, for example, a healthcare 
expert oﬀ ers scientiﬁ cally validated information that 
helps patients separate fact from ﬁ ction.228  
One of the most contentious sources of healthcare 
information for patients is prescription drug advertis-
ing directed to consumers—one of the fastest growing 
advertising categories.  Th ere is no doubt that such 
advertising plays an important role in informing 
consumers about various medical conditions and the 
availability of pharmaceutical treatments, and has 
triggered countless valuable conversations between 
patients and their caregivers.  At the same time, critics 
contend, such advertising has been accompanied by 
growth in inappropriate prescriptions at considerable 
cost to individual patients and to the healthcare sector 
in general.229   Proposals for greater FDA powers over 
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such advertising were oﬀ ered but were not included in 
the 2007 Amendments.230 
Patients as Research Assistants
Th e abundance of information has begun to change the 
relationship between patients and caregivers.  Accord-
ing to one survey, 52 percent of primary care physicians 
report that their patients are now arriving with print-
outs from web searches.231  Patients are gathering the 
latest research about a disease or a treatment, ﬁ nding 
notices of, and solicitations for, clinical trials, and giv-
ing them to their caregivers—along with folk remedies 
and charlatan’s cures.   
Th is may be annoying to some caregivers used to 
greater patient acquiescence, but thoughtful caregiv-
ers recognize that making the patient-caregiver 
relationship more of a partnership is fundamental to 
increased patient responsibility and, ultimately, better 
outcomes.232  Patient-provided research may also aid 
in ﬁ lling the gap between the publication/disclosure 
of research and its implementation in treatment 
regimes; patients and their families with their intense 
motivations to ﬁ nd solutions may prove to be helpful 
“research assistants” for their caregivers. 
Other Patient Contributions
Viewed through the lens of openness, patients are not 
only the beneﬁ ciaries of increased access to informa-
tion but they are among the most important sources 
of information for the healthcare system.  Patients 
provide the most direct evidence of what they are 
experiencing when they tell their stories.233  Th ey are 
also the most immediate source of their own and their 
family’s medical histories.  
Patients and their supporters also collectively con-
tribute as they lobby for funding for disease-speciﬁ c 
research.234  Th e Genetic Alliance, for example, rep-
resents over 600 groups of patients with diﬀ erent 
genetic conditions; the Alliance presses for funding 
for these conditions and also helps organize donations 
of tissue samples and solicits volunteers for clinical 
trials.235  In some cases patients and their support-
ers are directly funding research and clinical trials.  
Private foundations, often disease speciﬁ c, provided 
$5 billion in funding for research last year; in some 
cases, individuals actively recruited researchers who 
otherwise would have been working on diﬀ erent 
problems.236 
Another way patients, or those who care about them, 
are stimulating practical research and increased 
collaboration is via innovation prizes.  Th e use of 
contests, open to all with large prizes to stimulate 
creative activity, has a long and honorable history.237 A 
$10 million prize is now being oﬀ ered, for example, to 
whomever develops a cheaper, faster, gene-sequencing 
device, a breakthrough necessary to fully realize the 
beneﬁ ts made possible by increased genomic and 
pharmacogenomic information.238 
Increased patient activism is not an unalloyed good.  
Patient pressure for new treatments may help speed 
their development and approval, but there is a risk of 
rushing out remedies before they have been properly 
evaluated.239  Patient persistence may lead to over-
prescription or prescriptions for highly advertised 
drugs that are not as cost-eﬀ ective as other treatments; 
one partial explanation for the rise in drug-resistant in-
fections is that many caregivers have acquiesced in the 
over prescription of antibiotics in response to patient 
pressure to “do something.”   Patient reports about 
their symptoms are generally valuable, but like all 
stories may be inaccurate, biased, or at least in conﬂ ict 
with what is considered the best applicable science.240  
Patient lobbying can aﬀ ect healthcare funding in ways 
that may not reﬂ ect the best cost-beneﬁ t analysis for 
the society as a whole. (Although there are legitimate 
reasons to be concerned about this “politicization” of 
healthcare research priorities, one can still applaud 
the eﬀ orts by patients and their supporters to increase 
high-quality research and to speed the application of 
research to treatments and cures.)
Th e potential importance of patient input in another 
setting is just now being recognized.  Patient-recorded 
outcomes (PROs), the patient’s view of the impact of 
an intervention, are increasingly seen as valuable to 
certain clinical trials.  Studies have shown that PROs 
are, in some cases, better predictors of the eﬀ ectiveness 
of an intervention than clinical indicators.  In cancer-
related clinical trials, for example, PROs provided 
additional information on outcomes, particularly on 
how the intervention aﬀ ected the patient’s ability to 
lead a “normal” life —which is of great interest to 
patients. 241 
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Increased patient involvement has also been shown to 
have a positive eﬀ ect in a diﬀ erent way.  Greater patient 
participation in choosing among treatments—so-called 
“preference-sensitive care”—has reduced the use of the 
most aggressive, invasive, and expensive treatments 
by 23 percent over what the healthcare provider 
would otherwise have chosen.242  Even the attitudes 
that patients bring to ﬁ ghting their illnesses can have 
considerable impact on the success of treatments.243 
Patients are providing vital information in yet another 
way.  More and more data can be, and is beginning 
to be, collected from patients via remote monitoring.  
Remote monitoring is being integrated into more treat-
ment regimes in order to increase outpatient treatment 
while continuing observation and data collection, and 
to involve the patient more directly in his or her own 
care. 
Increased monitoring is facilitated by expanded Inter-
net access, as well as by the falling prices and greater 
functionality of communications-capable devices.  
Cell phones are being sold with glucose monitors and 
breathalyzers; digital cameras are being used to send 
pictures of meals for nutritional analysis; implants are 
communicating their host’s condition to the Web to 
be remotely scrutinized by his or her caregiver; remote 
devices that measure blood oxygen are reducing doctor 
visits and providing doctors with signs of developing 
problems.244  Devices worn by homebound patients 
now allow relatives to check if the patient has been 
immobile too long.245  New radiofrequency identiﬁ ca-
tion devices may ultimately allow remote monitors to 
determine if a refrigerator, or a vial of pills, has been 
opened, allowing inferences to be drawn about whether 
patients are eating or taking medications. 
Information can be passed both from and to the 
patient.  Remote devices can broadcast reminders 
for smokers to stop smoking.  Th ey can nag patients 
to take their medications—an important task when 
50 percent of prescriptions are never completed as 
prescribed.246  Such reminders can in fact change 
behaviors.247 
Th e same progress in information and communica-
tions technology that is allowing greater access to 
information and facilitating remote monitoring is help-
ing to improve rural America’s access to healthcare.  
Telemedicine is connecting patients far from medical 
centers to specialists who can obtain diagnostically 
relevant data or conduct consults at a distance.  Th e 
1996 Telecommunications Act recognized this oppor-
tunity and the FCC recently revised its rules to further 
encourage telemedicine.248  But issues regarding 
state-based licensing and medical-malpractice regimes 
still inhibit the growth of telemedicine, and questions 
about privacy and security, reimbursement for remote 
monitoring, data standards, and the interoperability of 
devices have not been fully resolved.249  
More Informed Healthcare Consumers
Greater access to information can help harness market 
forces to improve quality and reduce costs in health-
care.  Economists know that it is not possible for a 
market to function without information about quality 
and costs, but such information has been in short 
supply regarding hospitals, procedures, practitioners, 
and treatments. 
Patients often look to their caregivers for informa-
tion on cost and quality but most caregivers do not 
have this information.  Some limited information is 
available from the federal government, for example, 
on the costs of common medical procedures.250  Much 
more information could and should be made available 
given the vast amounts of payment data the federal 
government has accumulated; the total costs associated 
with a procedure, for example, are rarely disclosed.251  
(Costs for the same procedures surprisingly vary by 
up to 400 percent from region to region and the use of 
procedures can vary remarkably within regions, cast-
ing doubt on whether clinical-treatment regimes are 
being consistently followed. 252)  Th ere are encouraging 
signs that, as one leading consultancy wrote, “the 
federal government and leading private-sector payers 
are driving providers to make cost and quality data 
more transparent so that consumers can make better 
choices.” 253
Th e Department of Health and Human Service’s 
website (www.hospitalcompare.hhs.gov) provides 
comparative information on 19 diﬀ erent quality 
measures that the federal government gathers on 
every hospital.  It bases its ratings on what is done for 
the patient.  Th e data are available, however, on only 
a limited number of conditions and “ignores entire 
departments and specialties.”254  In February of 2007, 
HHS announced a plan to create local health-quality 
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information exchanges that would “collect information 
on the quality of local healthcare providers based on 
nationally established standards.  Th at data would 
then be pooled to create a public, nationwide quality 
reporting system.”255  
Private-sector actors, including web-health portals, 
see a potentially proﬁ table role in providing quality 
ratings to the public.  Using the same records relied 
upon by the federal government, Healthgrades (www.
healthgrades.com) oﬀ ers ratings focused on medical 
outcomes, adjusting them for the severity of the disease 
and the health of the patient; in addition it computes 
“patient-safety” ratings.256  Healthgrades charges 
hospitals for its complete reports and for allowing 
them to publicize their Healthgrade ratings.257 
Experiments suggest that even minimal disclosures 
can have beneﬁ cial results.  Th e release of risk-adjusted 
mortality data from cardiac-bypass surgery by doctors 
in New York, for example, had the salutary eﬀ ect of 
shining a spotlight on the worst performers, many of 
whom simply ceased to practice in New York.258  
Th ere are reasonable concerns raised about the New 
York study and its use of mortality data as the basis 
for the quality metric.  Th ere are intense debates about 
quality measures—as well as a number of initiatives to 
improve them.259  Care obviously needs to be taken in 
deﬁ ning the metrics, avoiding punishing hospitals and 
other providers that take on more diﬃ  cult cases, and  
preventing hospitals and caregivers from “gaming the 
system” by turning away sicker patients etc.  But the 
eﬀ orts to devise better quality measures and to gather 
and release quality and cost data are easily justiﬁ ed by 
the potential beneﬁ ts from unleashing market forces to 
improve healthcare. 
One would expect that many individuals, reliant until 
now largely on word-of-mouth recommendations, 
would respond to better information.  Th at assump-
tion underlies the establishment of consumer-directed 
health plans (CDHP’s) which are designed to provide 
incentives for healthcare consumers to make more 
informed purchasing decisions.  But given present 
practices in health insurance—limited deductibles, 
little choice among caregivers in many plans—it would 
be unduly optimistic to assume that the majority of 
insured individuals want to, or will soon become, 
skilled healthcare shoppers. 
Greater Openness and Incentives for 
Improving Healthcare
More important than the voluntary actions of indi-
vidual consumers will be the actions of employers in 
forcing the disclosure of cost and quality information 
and in responding to it.  Facing the economic pres-
sures that they do, ﬁ rms are already working to create 
incentives for improved medical outcomes and reduced 
costs, capping their costs, or even dropping health 
insurance altogether.260  Even more important, given 
the percentage of the nation’s healthcare costs that it 
pays, will be how the federal government deals with 
information regarding cost and quality.
Over the long run, eﬀ orts by the federal government 
and employers to harness market forces must go 
beyond the disclosure of information to more value-
conscious healthcare consumers.  Th ey will have to 
create strong incentives for improved care at lower 
costs.  
New clinical practice guidelines are likely to emerge as 
we strive to move toward evidence-based medicine.  But 
caregivers and institutions will need to be monitored 
to determine whether they are following new, as well as 
existing, guidelines.  As it is easier for individuals and 
organization to continue to do what they have been 
doing—a system at rest remains at rest—incentives are 
likely to be necessary to increase compliance.261 
Medicare has recently taken an important step in this 
direction.  Traditionally Medicare has covered the 
costs of all hospital procedures, even those required to 
deal with complications resulting from medical errors.  
Medicare announced in August 2007 that it will no 
longer reimburse hospitals for additional procedures 
incurred as a result of “preventable errors.”  Medicare 
will no longer pay, for example, for treatments for 
hospital-based infections.  Th ese are now considered 
preventable because of the development of guidelines 
and best practices which have been proven to eliminate 
their occurrence with little or no increase in costs.262 
State medical-error-reporting systems, which have 
helped identify the causes of preventable errors such 
as those that lead to hospital-based infections, provide 
useful inputs for any system designed to improve 
quality.  But many states do not require the report-
ing of medical errors.  Congress has established a 
voluntary national patient-safety network for reporting 
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and analyzing errors but regulations have not yet been 
issued for its implementation.263  A mandatory system 
may well be preferable given the grave consequences 
of many medical errors and the need to identify errors 
so that performance-enhancing feedback systems can 
operate.264 
Other information, not directly concerned with 
speciﬁ c procedures, drugs, or devices would also be 
valuable.  From the standpoint of improving healthcare 
and providing greater protection for patients, there 
seems to be little reason, for example, for any state to 
withhold information about disciplinary actions taken 
by its licensing boards against licensed healthcare 
providers. 
Openness and Caregivers
If patients in the past were sometimes seen as passive 
actors, caregivers were usually accorded great deference 
as highly educated sources of information and provid-
ers of treatments.  If patients are now empowered by 
new sources of information, some caregivers may now 
feel swamped by new kinds of information, less likely 
to be knowledgeable about all the interventions that 
patients have received as more disparate caregivers 
are involved, more time constrained in their interac-
tions with patients, more burdened by administrative 
requirements and battles with third-party payers, while 
receiving less respect and being accorded less status 
than in the times of Drs. Casey, Kildare and Welby. 
Caregivers and New Sources of Information
Caregivers, like patients, can beneﬁ t from dramatic in-
creases in genomic, pharmacogenomic, epigenomic and 
nutrigenomic information and the further evolution of 
evidence-based medicine.  If able to use this informa-
tion, they will be increasingly capable of personalizing 
treatments for their patients.  But while caregivers are 
expected to bring order to this information explosion, 
many may feel information “overload.”265  Th ey are 
expected to integrate new kinds of information which 
might not have been part of their medical education 
with evidence gleaned from massive databases and 
then determine the right treatment given the patient’s 
individual and family medical history, his or her 
symptoms, and the various diseases that this informa-
tion might suggest.  
Proponents of greater openness and more information 
recognize the dilemma of having too much informa-
tion and too little time to process it during a meeting 
with a patient.  Kaiser’s “Project Isobel” and similar 
work at the Veterans Administration and elsewhere 
are aimed at developing decision-support tools to help 
providers sort out possible diagnoses.266   Beyond 
providing possible diagnoses, these tools might suggest 
additional diagnostic questions, cue relevant tests, and 
list alternative treatment regimes. 
Decision-support systems cannot replace the insights 
that mark gifted diagnosticians.267  Th ey are not meant 
to reduce the practice of medicine to a mechanistic 
process overseen by automatons.  But with over 10,000 
known conditions and more than 1,900 existing 
clinical-practice guidelines, decision-support tools are 
increasingly needed for better and timelier decisions 
aimed at personalizing treatments in a data-rich 
environment.268  In theory these tools should be all 
inclusive, down to patient preferences for generic 
drugs, but the systems now being constructed have 
much more limited capabilities.269  
Even these limited systems are not easy to build.  A 
much simpler tool, such as a computerized physician-
order entry (CPOE) system for drugs, required consid-
erable development and testing eﬀ orts and substantial 
amounts of time before it began to help hospitals 
reduce medication errors and improve operating 
eﬃ  ciency.270  
In this new environment, caregivers, like patients, are 
also turning to their peers, utilizing support groups 
to exchange information as they do with adverse 
drug events.  Sermo (www.sermo.com), for example, 
provides an opportunity for registered physicians to 
exchange ideas and solicit help on diﬃ  cult medical 
diagnostic questions.271
The Attentive Caregiver
Patients contribute by telling caregivers how they feel. 
But caregivers may not be as “open” or receptive to 
what their patients are saying as they should be, or for 
as long as they should be.272  Observers have noted that 
many caregivers cease listening to their patients much 
too quickly, interrupting the patient or prematurely 
beginning the process of narrowing down potential 
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diagnoses even before the patient is ﬁ nished providing 
his or her story.273 
“Premature closure” is likely to aﬀ ect diagnostic 
quality.  Estimates of faulty diagnoses range as high as 
30 percent; misdiagnoses are the source of almost 60 
percent of malpractice claims.274  Increased time pres-
sure on patient-caregiver interactions only heightens 
this problem 
Th e use of decision-support systems may allow caregiv-
ers to spend more time actually listening to patients.275  
Similarly, the use of e-mail and other electronic com-
munications tools should, among other eﬀ ects, enable 
patients to ﬁ ll out forms and provide information in 
advance rather than during the visit, allowing richer 
and fuller conversations.276
Openness and Information Provided by 
Caregivers
Caregivers have unique tacit information about their 
practices—what and how processes work or don’t 
work, what patients are likely to do in a given situation, 
and what can or can’t be accomplished under speciﬁ c 
conditions.  Th is information is often diﬃ  cult to 
codify and transfer, but it is critical for developing ef-
fective treatment regimes.  Greater involvement in the 
development of treatment regimes or clinical trials by 
experienced caregivers would allow tacit, experience-
based knowledge to better inform the necessary 
decisions.
Th e root of the word doctor is from the Latin docere—
to teach.277  Doctors have always taught patients about 
their illnesses.  Th ey are increasingly educating them 
about how to maintain and improve their health.  
Now they can help patients deal with the information 
tsunami by teaching them how to evaluate medical 
information.  In doing so, doctors can improve their 
patients’ performance both as research assistants and 
healthcare consumers.
Surveys have shown that 8 percent of caregivers do 
not provide their patients with a complete range of 
treatment alternatives based on their own moral views 
about one or more of the alternatives.278  Eighteen 
percent of caregivers do not provide their patients with 
information about doctors whose work they believe is 
unsatisfactory.279  Other caregivers may not provide 
information on treatment alternatives that they judge 
to be too expensive or inappropriate for the patient 
for some reason.  If shared decision-making between 
patient and caregiver is desirable, then it follows that 
patient participants should be aware of any limits set 
by their caregivers that prevent the patients from fully 
evaluating the treatment choices available.280 
Caregiver Confl icts 
Caregivers have traditionally played the principal role 
in determining what treatment a patient will receive.  
Recently there has been a dramatic increase in the 
ﬁ nancial stakes that caregivers have in treatment alter-
natives.281  Th ese ﬁ nancial interests—whether they are 
in outpatient treatment facilities, hospitals, procedures, 
etc.—have been demonstrated to aﬀ ect a caregiver’s 
objectivity, yet there is little information available 
to patients regarding such interests.282  Increased 
openness would require, at the least, that the ﬁ nancial 
interests of the caregiver in any aspect of treatment be 
disclosed.  Medicare has recognized these conﬂ icts and 
is cutting back on “self-referrals.”283 
Narrowing the interval between discovery and clinical 
practice is, as we noted earlier, a major challenge.  One 
way to shorten this interval is to help caregivers stay 
informed of developments in their ﬁ eld. 
Pharmaceutical companies play a crucial role in turn-
ing research into treatments.  Th ey oﬀ er their expertise 
in new treatments to caregivers and justify visits by 
their sales representatives to caregivers, in part, on the 
basis that the representatives help in keeping caregivers 
current.284  Th ere is no doubt that they do provide 
useful information.285  But they also often come 
bearing gifts, including entertainment tickets and free 
samples; they sometimes stay for (and provide) lunch, 
and suggest non-FDA approved uses and higher doses 
for the drugs they represent.286  Research suggests that 
these visits can aﬀ ect what caregivers prescribe.287
In 2002, the American Medical Association estab-
lished a voluntary code governing the receipt of gifts 
including meals.  The Pharmaceutical Research and 
Manufacturers of America has also established guide-
lines including, for example, prohibiting gifts of free 
tickets.  Recent surveys show, however, that four out 
of five doctors would allow pharmaceutical company 
representatives to buy them meals and 7 percent of 
caregivers are willing to accept free tickets.288  
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Policymakers should support other, more disinter-
ested, sources for the continuing education of caregiv-
ers.289  More information should be available about 
the relationship between caregivers and those, other 
than patients, who profit from their decisions, so that 
patients can better evaluate treatment alternatives.290 
Lawmakers at the federal and state levels have taken 
steps toward requiring such disclosures.  Legislation 
has been introduced in Congress that would force 
pharmaceutical companies to report all payouts in 
excess of $25 including gifts to physicians to be pub-
lished in a national on-line registry.291 
Some states such as Vermont already require drug 
companies to reveal payouts to physicians but the long-
term effects of these laws are not yet known.  In the 
short run they do not appear to have reduced pharma-
ceutical payments to caregivers; in Vermont payments 
have increased since 2002 when the disclosure law was 
passed. 292 
Pharmaceutical companies target visits by their sales 
representatives using state records of prescriptions by 
caregivers; they focus on caregivers who prescribe the 
most.293  Some pharmaceutical companies even provide 
direct financial incentives via rebates or other means to 
those who prescribe their drugs most often.294
A number of states have attempted to limit access 
by pharmaceutical companies to the records of what 
caregivers prescribe but these restrictions have been 
challenged.295  Openness generally favors the availabil-
ity of more rather than less information but there is an 
argument that caregivers should be able to opt out of 
these states systems to the extent necessary to prevent 
the use of their prescribing records for marketing 
purposes; alternatively a national or state level do-not-
call/visit list might be created.
Recommendations Regarding Expanding 
Openness for Patients and Caregivers
The federal government should increase the provision 
of consumer-oriented healthcare information based on 
the best scientific information available.
The National Library of Medicine and other fed-
eral healthcare-research agencies should work with 
private-sector providers of healthcare information and 
web-search firms to determine if standards or other 
measures could be implemented to assist users search-
ing for accurate healthcare information.
The federal government should more aggressively 
move to disclose information on the cost and quality 
of healthcare procedures with careful attention paid to 
the development of appropriate metrics and the quality 
of the available data.
The federal government should lead efforts to monitor 
compliance with clinical practice guidelines and use 
financial incentives to encourage compliance.  The 
federal research agencies should support research on 
the development and evaluation of decision-support 
systems for caregivers.
The federal research agencies should support research 
on the appropriate use of patient-reported outcomes 
and preference-sensitive care.
State governments should provide access to informa-
tion on disciplinary actions taken by licensing boards 
regarding licensed healthcare providers.
The federal government should work with state 
governments and practice groups to reduce barriers to 
the practice of telemedicine resulting from state-based 
licensing and malpractice rules.
The federal government should re-examine its health-
care reimbursement policies to determine if changes 
are necessary to foster the development of appropriate 
telemedicine practices, to encourage the use of remote-
monitoring devices and the evaluation of the data they 
provide, to reflect efforts by caregivers to help patients 
monitor chronic conditions, and to compensate 
caregivers for communicating with patients outside of 
officers hours in order to improve patient care.296
The appropriate federal agencies should work with the 
appropriate private-sector groups to develop model 
disclosure requirements dealing with the financial 
interests of caregivers in treatments they recommend.
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Chapter 7: Openness and Public Health
Th e Human Genome Project demonstrated the power 
of openness when researchers were collaborating at 
the microscopic level.  Th e Severe Acute Respiratory 
Syndrome (SARS) outbreak of 2002-2003 demon-
strated the need for openness in public health when 
even telescopes could not help the global public-health 
community see an oncoming epidemic.  
Th e SARS outbreak began quietly in China.  Th e 
Global Public Health Intelligence Network, which 
gathers information from various sources around the 
world, helped identify the start of the SARS outbreak 
from articles published in China about a mysterious 
illness aﬀ ecting otherwise healthy people, even before 
any oﬃ  cial reports were received by the WHO.297  As 
the outbreak gathered momentum it was clear that 
greater resources were needed—and scientists and 
public-health workers around the world began an eﬀ ort 
to identify the disease and to formulate responses.  
Th e WHO helped to coordinate the work of multiple 
laboratories to ensure the availability of appropriate 
research materials and to reduce duplication of eﬀ ort.  
Eventually the outbreak was contained.298 
Lessons of the SARS Outbreak
Th ere are some obvious lessons to be gained about 
the value of openness in the public-health arena when, 
given our interconnected world, diseases can be spread 
at close to supersonic speed.  Th e ﬁ rst is the impor-
tance of obtaining and sharing information locally 
and globally.  Even given heroic actions by individual 
doctors and ordinary citizens to address the SARS 
outbreak, it was not until authorities in China were 
prepared to acknowledge that a problem existed and to 
provide relevant data that the capabilities of the global 
scientiﬁ c community could be mobilized.  
Th e Centers for Disease Control and Prevention are 
now linking public-health laboratories around the 
world to allow, for example, the rapid identiﬁ cation 
of food contamination through the comparison of 
the DNA ﬁ ngerprints of the contaminant.299  Th e 
Center for Infectious Disease Research and Policy and 
the Pew Center on the States have created a web site 
(www.pandemicpractices.org) to allow public health 
professionals to exchange information and improve 
pandemic planning.300  On the local level in the United 
States, though, only 13 states are capable of being 
interconnected with the Public Health Information 
Network to be able to share public-health information.  
Th e number is expected to grow to 40 by 2012, but 
there is still much to be done.301 
Th e second lesson is that almost any facility designed 
for collaboration can help in providing an eﬀ ective 
public-health response.  For example, collaborative 
search tools developed by Google are being provided 
to disaster-response organizations to facilitate early 
detection of potential healthcare disasters.302  
Openness and Contributions from Less 
Obvious Sources
Other lessons may be less obvious.  A corollary to the 
ﬁ rst lesson is that countries that share information and 
provide materials essential to identifying a disease and 
ﬁ nding a cure—often lower-income countries where 
new diseases are more likely to emerge—are provid-
ing the global health establishment with materials 
of extraordinary value.  Th ey understandably want 
their contributions recognized.  Th ey are increasingly 
resistant to arrangements that they view as providing 
the bulk of the beneﬁ ts, including supplies of vaccines 
and licensing fees or royalties, to other, more economi-
cally advanced countries.  
Recent examples of foreign governments withholding 
sample materials suggest that this issue is likely to 
become more pressing in the future.303  In response 
to these concerns, the WHO is now considering 
stockpiling vaccines to ensure that poorer countries 
that provide data and tissue samples but that might not 
be able to aﬀ ord costly medicines will be guaranteed 
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help in dealing with healthcare threats to their own 
citizens.304 
Sometimes the mutuality of beneﬁ t can only be 
recognized over time.  It is clear that researchers in 
sub-Saharan Africa receive substantial beneﬁ ts today 
from the WHO’s Hinari Project providing them ac-
cess to scientiﬁ c literature.  What is not yet visible are 
the contributions that these researchers are more likely 
to make in the future because of their access today to 
research journals and better research tools.305  
What is also not yet fully appreciated are the potential 
beneﬁ ts available to researchers from data collection 
by, and the tacit knowledge of, individuals in these 
lower-income countries.  Important contributions can 
come from quite unexpected sources.  More-open, 
more-responsive systems for gathering data should 
be designed to reﬂ ect this.  Th e International Health 
Regulations, for example, are being changed to allow 
the WHO to accept disease reports from sources 
other than governmental oﬃ  cials and, as one observer 
noted, to empower “ordinary people to notify the right 
authorities, without getting snarled in politics, com-
mercial interests, or bureaucracy.”306  In one extraordi-
nary example of an unexpected source, Nathan Wolfe, 
an epidemiologist at UCLA, has established in Cam-
eroon a “network of hunters to supply blood samples 
from themselves and the animals they eat to check for 
new viruses—[and] to report quickly any novel animal 
diseases.”307  Greater openness in public health, can, 
and should, be stretched to the ends of the earth.
Public health eﬀ orts depend on gathering informa-
tion from a wide variety of sources, including some of 
society’s most vulnerable populations.  It is therefore 
important to consider who will have access to the data.  
Should, for example, the information that is gathered 
for public health purposes be readily available to law 
enforcement oﬃ  cials?  If so, what impact would such 
access have on the willingness of individuals to provide 
critical information?  Our society has struggled with 
this question in the context of the HIV Aids epidemic 
and it is likely that we will continue to wrestle with the 
issue again.308  
Recommendations Regarding Openness and 
Public Health
Th e federal agencies should lead eﬀ orts to support 
multilateral surveillance networks and cooperative 
activities.
Th e United States should recognize, in material 
ways, the contributions made by other, particularly 
lower-income, countries that provide valuable data and 
samples.
Priority should be given to the electronic interconnec-
tion of federal and local public-health authorities. 
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When proponents of greater openness give examples 
of its value they rarely point to medical devices.  Th ey 
are more likely to cite innovations in general-purpose 
personal computers that are the result of individuals 
“tinkering” with them—making improvements in 
hardware and software without seeking approval from 
the government or the manufacturer.309 
Changes in Medical Devices
Medical devices are increasingly coming to resemble 
these computing devices.  More medical devices have 
computational capabilities; more devices are controlled 
by software that can be modiﬁ ed to cause the device to 
do new things or to do existing things diﬀ erently.310  At 
the same time, the open-source movement has demon-
strated that software is almost inﬁ nitely malleable and 
that millions of people are willing to suggest ways to 
improve it.311
Eric Von Hippel of MIT points out in his book, 
Democratizing Innovation, that “lead users”—those 
with deep knowledge of their own needs and the 
resources to satisfy them—have played an important 
role in innovation.312  Von Hippel’s work demonstrates, 
in particular, that much of the innovation in the area of 
scientiﬁ c instruments came from users of these instru-
ments rather than from their manufacturers.  Given 
this history, it would be surprising if “lead users” e.g. 
caregivers, aren’t tempted to modify their tools, which 
are medical devices.  Moreover, there are situations 
where the need to customize devices for an individual, 
such as in the ﬁ eld of prosthetics, seems to invite user-
driven innovation.313 
The FDA’s Responsibility
At the same time that many medical devices are be-
coming more susceptible to modiﬁ cation by users, they 
continue—and justiﬁ ably so—to be subject to review 
by the FDA.  FDA jurisdiction over medical devices is 
designed to ensure that they perform as promised and 
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do it safely.314  If the device is approved by the FDA, it 
is exempt from state liability rules in the normal course 
of its operation, reducing the manufacturer’s potential 
state product-liability exposure.315
Th e FDA approves a device “as is”—with the existing 
hardware and software.  As with warranties from 
computer, electronics, and automobile manufacturers, 
the FDA’s approval is voided if “the hood is opened” 
and changes are made.316 
Can the potential for greater user-driven innovation in 
medical devices be reconciled with the FDA’s mission 
to ensure the safety and eﬃ  cacy of medical devices?  
It may not be possible for all of the technically adept 
caregivers to successfully resist the challenge to hack/
improve FDA-approved medical devices.   Given this, 
could and should the FDA provide some form of a 
“safe harbor” for physicians and physician-directed 
programmers where they might “tinker” without 
penalty, similar to the safe harbor the FDA provides 
for physicians who prescribe drugs for non-FDA ap-
proved purposes and for  pharmacists who customize a 
drug compound at the direction of a physician?  Could 
and should the FDA authorize small-scale experi-
ments with modiﬁ ed hardware or software overseen by 
institutional review boards and based on the informed 
consent of patients?  Could and should the FDA 
create a less intensive (and less-costly) review process 
for minor software changes in programmable medical 
devices analogous to the less-intensive FDA review 
processes for minor changes in already-approved drugs, 
while requiring rigorous reporting of adverse events?  
Could and should the FDA delegate, to a specialized 
expert body outside of the FDA, the power to review 
and recommend proposed changes for approval?  Or 
will the acknowledged complexity of software interac-
tions and the critical mandate to ensure patient safety 
prevent the kind of innovation we would expect when 
information and communications technologies inﬁ l-
trate a new area of practice? 
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One other point might be made about the openness 
of medical devices.  If one examines a device-rich 
environment such as a hospital intensive-care unit, one 
is struck by the very large number of devices making 
critical measurements, with each device providing 
valuable data.  But in many instances the output of an 
individual device is not in a form that can be captured, 
recorded, and manipulated together with the outputs 
of the other devices.  Just as the data underlying 
clinical trials need to be in machine-discoverable, 
searchable, and manipulatable formats to be of greatest 
use, the value of the outputs of medical devices would 
be enhanced if they were standardized in a similar 
fashion. 
Recommendations Regarding the Openness of 
Medical Devices
Th e FDA should begin an inquiry into the appropri-
ate long-term regulatory treatment, consistent with 
patient-safety needs, of software-controlled medical 
devices given the innovation potential demonstrated by 
the open-source software movement and the history of 
user-led innovation in scientiﬁ c instruments.
Th e FDA should engage the private-sector medical-
device community and the federal research agencies 
to stimulate greater interoperability among medical 
devices and greater standardization of data outputs to 
facilitate the creation and use of integrated data sets.
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Th e returns to increased openness in research dem-
onstrate the potential for societal gains from greater 
openness.  But is greater openness compatible with 
private returns in markets downstream from research?
As the open source software movement has grown, 
some critics have asserted that the model, which makes 
computer source code available to all, is incompatible 
with the proﬁ t motive, a threat to investment  in “real,” 
(proprietary) software, and dependent on the altru-
ism of programmers.317  Altruism is among the many 
reasons that programmers participate in the open-soft-
ware movement and that other individuals contribute 
their time and eﬀ ort to other “open” products.  But it is 
not the only reason. 
Openness, in the open-source software movement, and 
in other manifestations we have described, results from 
many diﬀ erent motivations and is compatible with the 
creation of private value.  It reﬂ ects a newly emerging 
theory of how value can be created.318  
Th e creation of private economic value via innovation 
has long been linked with the ability of a creator to 
control his or her creation.  Th e creator can then 
monetize the value of the creation by charging others 
for the right to access, replicate or modify it.  Open-
ness, on the other hand, assumes that the public and 
private value of a creation can be increased by sharing 
the creation as broadly as possible, so that others 
with diﬀ erent experiences, knowledge, insight, and 
incentives can contribute to and improve it.  Th is idea 
of how to create value is the mirror image of creating 
value through control.  
We do not always have to choose one model or the 
other.  But given the long history of more-closed busi-
ness models, it is noteworthy that the idea that greater 
openness, appropriately applied, can help build better 
businesses is gaining wider acceptance.319
Henry Chesbrough, of the University of California 
at Berkeley, in his book, Open Business Models, 
describes several business models that companies can 
embrace to increase their openness and improve their 
performance.320  He analyzes two “syndromes”—“Not 
Invented Here” and “Not Sold Here”—that have 
inhibited organizations from becoming more open by 
drawing upon innovations from outside the organiza-
tion and from proﬁ ting by sharing their own innova-
tions with others.321
Not Invented Here
We all have experienced the rejection of ideas or 
suggestions because they were “not invented here.”322  It 
is not hard to understand why this syndrome has such 
power.  By deﬁ nition, an innovation from outside an 
organization cannot reﬂ ect an intimate understanding 
of the organization.  Such an understanding is only 
possible inside an organization.  An innovation from 
outside arguably cannot be as good because it has 
not passed the internal approval screens to which an 
inside innovation is subject.  If an outside innovation 
is signiﬁ cant, the fact that it came from outside may 
be taken by others as a sign that the organization’s 
own vehicle for innovation is underperforming or even 
unnecessary.   
Over the years, some of the most prominent and 
innovative organizations encouraged a “not-invented-
here” attitude.  Proctor and Gamble (P&G), for 
example, built a widely admired product development 
process closed to outsiders.   But more recently P&G 
has recognized the vast amount of creative work done 
outside of its R&D units and the potential gains 
available from tapping into knowledge and creativity 
dispersed globally—both in terms of the costs of 
development and the time required to bring a product 
to market.323  Instead of “not invented here” P&G is 
urging its researchers to ﬁ nd innovations that can be 
labeled “proudly developed elsewhere” and “reapplied 
with pride.”324 
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Even large pharmaceutical companies that tradition-
ally have sought to develop their own drugs and 
protect them with a barricade of patents rather than 
relying on the creative work of others are exhibiting 
greater openness.  As the CEO of Novartis stated, 
“we can’t possibly do it all ourselves.”325  Th e CEO of 
Glaxo SmithKline announced that managers will be 
rewarded for nurturing products whether developed 
in-house or acquired from the outside.326  More open 
attitudes have led to links between large pharmaceuti-
cal companies and smaller outside ﬁ rms, particularly 
biotech and diagnostic companies, as well as a greater 
willingness on the part of large pharmaceutical compa-
nies to collaborate with each other, and with academic 
and government researchers such as in the SNP 
Consortium.327  It is telling that InnoCentive, one of 
the premier examples of bringing outsiders into the 
R&D process, began as a subsidiary of Eli Lilly.328 
Not Sold Here
Th e other syndrome, “Not Sold Here,” also is becom-
ing less useful in deﬁ ning and predicting organiza-
tional behavior.  “Not sold here” is when an organiza-
tion doesn’t attempt to pursue a direction or capture 
the value of an idea that it has generated because it is 
outside the core activities of the organization—what 
the organization “sells.”  One example would be a 
company’s refusal to sell or lease research results 
that have not led to the company’s development of a 
product.329  Again, it is not hard to understand the 
reasoning.  A company’s employees might fear that its 
rivals will beneﬁ t from their ideas—even if their own 
company will not.  Maybe the other company will take 
the idea and make it into a brilliant success.  Who 
would want to acknowledge responsibility for letting 
that now successful idea get away?330  Th ere is also 
value for competitors in learning about what doesn’t 
work so they can avoid research “rabbit holes”—why 
make life easier for rivals?
Yet here, too, changes are in the wind.  Novartis is 
making the raw data from its genomic research on 
Type 2 diabetes broadly available.  Perhaps this is due, 
in part, to altruism, but observers point to the beneﬁ ts 
for Novartis, including the building of stronger 
relationships with leading academic researchers and 
the stimulation of other work in the area.331  Merck, 
for example, has invested millions in a public genome 
database to stimulate research it hopes will help to 
develop its core “end products.”332
Other pharmaceutical companies are collaborating 
with companies (often smaller and more focused) by 
making available, from their large libraries of small 
molecules, certain molecules that they are not pursu-
ing, with the prospect of sharing in any proﬁ ts that the 
other company might obtain.333  (One can even imagine 
an Internet-enabled auction where companies with 
such molecular libraries might progressively “open” 
them, providing more and more information about 
speciﬁ c molecules they are not pursuing in return for 
increased payments or larger shares of any downstream 
proﬁ ts.)
We have not addressed in any detail possible public-
policy initiatives to encourage more open business 
models—companies will make their choices about 
the appropriate degree of openness based on their 
own situations.  But others have made proposals, 
for example, to provide tax incentives for greater 
collaboration.334  In some cases, public policies have 
been adopted that may discourage greater openness.  
P&G, for example, had a policy in the past of making 
research results available after three years if the com-
pany decided not to pursue them.  P&G provided these 
results to colleges and universities to be developed and 
commercialized but ceased doing so when the tax code 
was changed.  Perhaps the tax code should not favor 
openness, but it should not discourage it either.
Companies seeking a proﬁ t understand the importance 
of innovation and are increasingly building global strat-
egies to locate and beneﬁ t from innovations around the 
world.  Th e beliefs underlying the move toward greater 
openness—that more people can beneﬁ t from more 
information and that more people can make unique 
contributions based on their interests, experiences, 
and insights—may be captured in the maxim: All 
other things being equal, the team with the most smart 
people wins.*  Th ere are obviously many diﬀ erent kinds 
of “smartness.”  Diﬀ erent kinds are needed in diﬀ erent 
circumstances—just as the optimal degree of openness 
will depend on the speciﬁ cs of a situation.  But greater 
openness oﬀ ers an opportunity to beneﬁ t from the 
contributions of more people, whether to create public 
or private value.*  Coined by DCC project director Elliot Maxwell.
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Openness is not binary; information or processes are 
not open or closed.  They sit on a broad continuum 
stretching from closed to open, based on their accessi-
bility and responsiveness.  And the most open result is 
not always the best result, depending on the particular 
goals to be accomplished and the specific circum-
stances.  But greater openness can be of great benefit, 
from the academic world to the business world, from 
the research endeavor to the delivery of treatment, 
from the development of medical devices to the foster-
ing of a more-responsive global public-health system.  
Greater openness enhances, and is in turn fostered by, 
increased collaboration.
This report is a first attempt to identify some of the 
areas that are being changed by greater openness.  It 
is not exhaustive and, as information and communica-
tions technologies suffuse the healthcare arena, the 
list is likely to grow over time.  We hope that others 
will be encouraged to develop this theme and spotlight 
other areas where openness can help us transform 
today’s pre-industrial and wasteful healthcare system 
toward one that is more responsive, more efficient, 
more personalized, more evidence-based, and more 
oriented toward fostering life-long good health. 
Conclusion
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CE  Circulo de Empresarios
  Madrid, Spain
CEAL  Consejo Empresario de America Latina
  Buenos Aires, Argentina
CEDA  Committee for Economic Development of Australia
  Sydney, Australia
CIRD  China Institute for Reform and Development
  Hainan, People’s Republic of China
EVA  Centre for Finnish Business and Policy Studies
  Helsinki, Finland
FAE  Forum de Administradores de Empresas
  Lisbon, Portugal
IDEP  Institut de l’Entreprise
  Paris, France
IW  Institut der deutschen Wirtschaft Koeln
  Cologne, Germany
 Keizai Doyukai
  Tokyo, Japan
SMO  Stichting Maatschappij en Onderneming
  Th e Netherlands
CED Counterpart Organizations
Close relations exist between the Committee for Economic Development and independent, nonpolitical research 
organizations in other countries. Such counterpart groups are composed of business executives and scholars 
and have objectives similar to those of CED, which they pursue by similarly objective methods. CED cooperates 
with these organizations on research and study projects of common interest to the various countries concerned. 
Th is program has resulted in a number of joint policy statements involving such international matters as energy, 
assistance to developing countries, and the reduction of nontariﬀ  barriers to trade.
Committee for
Economic Development
2000 L Street N.W.
Suite 700
Washington, D.C. 20036
202-296-5860 Main Number
202-223-0776 Fax
1-800-676-7353
www.ced.org
Harnessing Openness to
Transform American Health Care
A Report by the Digital Connections Council of 
the Committee for Economic Development
